

1 ***Neuroplastin* genetically interacts with *Cadherin 23* and**
2 **the encoded isoform Np55 is sufficient for cochlear hair**
3 **cell function and hearing**

4

5 Sherylanne Newton¹, Fanbo Kong², Adam J Carlton², Carlos Aguilar¹, Andrew Parker¹, Gemma F
6 Codner³, Lydia Teboul³, Sara Wells³, Steve DM Brown¹, Walter Marcotti^{2,4} & Michael R Bowl^{1,5*}

7

8 ¹Mammalian Genetics Unit, MRC Harwell Institute, Harwell Oxford, Oxfordshire, OX11 0RD, UK.

9 ²School of Sciences, University of Sheffield, Sheffield, S10 2TN, UK.

10 ³Mary Lyon Centre, MRC Harwell Institute, Harwell Oxford, Oxfordshire, OX11 0RD, UK.

11 ⁴Sheffield Neuroscience Institute, University of Sheffield, Sheffield, S10 2TN, UK.

12 ⁵UCL Ear Institute, University College London, 332 Gray's Inn Road, London, WC1X 8EE, UK

13

14 *Corresponding author

15 E-mail: m.bowl@ucl.ac.uk

16

17 Short title: NEUROPLASTIN-55 is sufficient for hearing

18 Keywords: Hearing, deafness, hair cell, stereocilia, cell adhesion molecule, Neuroplastin, mouse,

19 Cadherin 23

20

22 Abstract

23 Mammalian hearing involves the mechano-electrical transduction (MET) of sound-induced fluid
24 waves in the cochlea. Essential to this process are the specialised sensory cochlear cells, the inner
25 (IHCs) and outer hair cells (OHCs). While genetic hearing loss is highly heterogeneous, understanding
26 the requirement of each gene will lead to a better understanding of the molecular basis of hearing and
27 also to therapeutic opportunities for deafness. The *Neuroplastin* (*Nptn*) gene, which encodes two protein
28 isoforms Np55 and Np65, is required for hearing, and homozygous loss-of-function mutations that affect
29 both isoforms lead to profound deafness in mice. Here we have utilised several distinct mouse models
30 to elaborate upon the spatial, temporal, and functional requirement of *Nptn* for hearing. While we
31 demonstrate that both Np55 and Np65 are present in cochlear cells, characterisation of a Np65-specific
32 mouse knockout shows normal hearing thresholds indicating that Np65 is functionally redundant for
33 hearing. In contrast, we find that *Nptn*-knockout mice have significantly reduced maximal MET currents
34 and MET channel open probabilities in mature OHCs, with both OHCs and IHCs also failing to develop
35 fully mature basolateral currents. Furthermore, comparing the hearing thresholds and IHC synapse
36 structure of *Nptn*-knockout mice with those of mice that lack *Nptn* only in IHCs and OHCs shows that
37 the majority of the auditory deficit is explained by hair cell dysfunction, with abnormal afferent synapses
38 contributing only a small proportion of the hearing loss. Finally, we show that continued expression of
39 NEUROPLASTIN in OHCs of adult mice is required for membrane localisation of Plasma Membrane
40 Ca^{2+} ATPase 2 (PMCA2), which is essential for hearing function. Moreover, *Nptn* haploinsufficiency
41 phenocopies *Atp2b2* (encodes PMCA2) mutations, with heterozygous *Nptn*-knockout mice exhibiting
42 hearing loss through genetic interaction with the *Cdh23^{ahl}* allele. Together, our findings provide further
43 insight to the functional requirement of *Neuroplastin* for mammalian hearing.

44

45

46

47 **Author Summary**

48 Sensorineural hearing loss, caused by problems with sensory cells in the cochlea or the auditory
49 nerve, is the most common type of hearing loss. Mutations in *Neuroplastin* have already been implicated
50 in deafness in mice. We have used mutant mouse models to investigate where *Neuroplastin* is
51 expressed in the cochlea and its function. When mice do not express a functioning copy of *Neuroplastin*
52 they have disruptions to the primary sensory synapse. We show that although synaptic disruption
53 contributes to the loss of hearing function it is not the primary cause. Instead, continued expression of
54 *Neuroplastin* is needed to maintain the localisation of Plasma Membrane Ca^{2+} ATPase 2 channels which
55 help regulate calcium flow. We have also shown that two types of NEUROPLASTIN protein (isoforms)
56 are both expressed within the cochlea, although only one of these isoforms needs to be expressed for
57 normal hearing. Finally, we also demonstrate that the hearing loss caused by the absence of
58 *Neuroplastin* is made worse when combined with a common mutation within a gene called *Cadherin 23*
59 (*Cdh23^{ahl}*). This is an important finding as although there are currently no human patients with an
60 identified NEUROPLASTIN mutation, it may be involved in human deafness in combination with other
61 mutations.

62

63 **Introduction**

64 The mammalian cochlea is an extremely complex and organised structure consisting of multiple
65 cell types that act in concert to convert sound into neuronal signals. In particular, within the organ of
66 Corti are two functionally distinct sensory cells: the inner hair cells (IHCs), which relay sound stimuli to
67 the brain via the release of glutamate from ribbon synapses onto type I spiral ganglion neurons; and the
68 outer hair cells (OHCs) which mechanically amplify sound stimuli through the generation of voltage-
69 dependent axial forces on the organ of Corti. The function of both IHCs and OHCs is driven by
70 mechano-electrical transduction (MET) channels located at the tips of modified microvilli called
71 stereocilia at the apex of each cell, activated following deflection of the stereocilia bundle. Though we

72 now have a good understanding of the specific function of auditory hair cells, it is still largely unknown
73 how the functional development of these complex sensory cells is orchestrated at a molecular level.
74 Calcium ions (Ca^{2+}) have several essential roles in the cochlea, including contribution to the total MET
75 current [1], and driving adaptation of the MET channels, reducing their open probability [2]. Highly
76 coordinated Ca^{2+} -signaling is also required for the maturation of afferent synapses on both IHCs [3] and
77 OHCs [4], and in mature IHCs, the influx of Ca^{2+} , primarily through $\text{Ca}_v1.3$ channels located at each
78 active zone, facilitates the release of vesicles onto the afferent terminals.

79 NEUROPLASTIN (ENSMUSG00000032336), together with BASIGIN
80 (ENSMUSG00000023175) and EMBIGIN (ENSMUSG00000021728), comprise a small family of neural
81 cell adhesion molecules (NCAM), which are an integral component of the synaptic membrane and are
82 proposed to mediate cellular processes such as synaptic plasticity and neuronal differentiation [5-9].
83 Furthermore, the study of mouse mutants has shown a role for this family in sensory function, including
84 vision and hearing [10, 11]. Of these, the role of NEUROPLASTIN in hearing is the most studied, with
85 loss-of-function mutations causing profound early-onset hearing loss [12, 13]. However, there are many
86 outstanding questions regarding the role and requirement of NEUROPLASTIN for mammalian hearing.
87 The *Neuroplastin* gene (*Nptn*) encodes two protein isoforms: the larger Np65 that consists of three
88 extracellular Ig domains (Ig1-3), a transmembrane domain and a short intracellular C-terminal; and,
89 Np55 in which exon 2 is skipped to produce a shorter NEUROPLASTIN without Ig1 [14]. Np55 is
90 reported to be localised to outer hair cell (OHC), but not inner hair cell (IHC) stereocilia, where it is
91 required for their correct coupling to the tectorial membrane [13]. Localisation of NEUROPLASTIN has
92 also been reported at the basolateral membrane of IHCs, where it plays a critical role in the formation
93 of mature ribbon synapses, which was hypothesised to involve Np65 [12]. To date, all of the *Nptn* alleles
94 studied in relation to hearing involve loss of both Np55 and Np65 [12, 13, 15].

95 Here we have studied several *Neuroplastin* knockout mouse models to further elaborate upon
96 the role of this NCAM in mammalian hearing. We find that deletion of Np65 alone does not cause
97 deafness, thereby demonstrating that Np55 is sufficient to support auditory development and function.

98 Moreover, we demonstrate that while IHC synaptopathy is a significant pathological feature, synapse
99 formation does not require Np65, nor is it the main driver of hearing loss in *Nptn*-null mice. Furthermore,
100 continued expression of *Neuroplastin* in adulthood is required to maintain hearing function. Finally, we
101 demonstrate that the expressivity of the *Nptn* loss-of-function auditory phenotype is potentiated by strain
102 background, showing a genetic interaction between *Nptn* and the strain-specific *Cadherin 23*
103 (Otocadherin, ENSMUSG00000012819) mutant allele, *Cdh23^{ahl}*, that is present in C57BL/6 mice. This
104 effect is likely mediated through the NEUROPLASTIN-dependent localisation of PMCA2 channels in
105 stereocilia.

106 Results

107 Both Np65 and Np55 are cochlear expressed and absent in the *Nptn^{tm1b}* 108 deafness mutant

109 To gain insight into which NEUROPLASTIN protein isoforms are required for hearing, an RT-
110 PCR study was undertaken to determine the *Nptn* transcripts present in wild type whole cochleae.
111 Transcripts relating to the two main protein isoforms, Np65 (*Nptn-212*, ENSMUST00000177292, exons
112 1 - 8, 397aa) and Np55 (*Nptn-201*, ENSMUST00000085651, exon 2 skipped, 281aa), were amplified.
113 These differ by the presence or absence of exon 2 that encodes Ig1, respectively (Fig 1A). To assess
114 the presence of both Np65 and Np55 isoforms in mouse cochlear tissue, Western blotting was
115 undertaken utilising two commercially-available anti-NEUROPLASTIN antibodies: an anti-pan-Np
116 antibody that detects both Np65 and Np55, and an anti-Np65-specific antibody (Fig 2A). For negative
117 control lysates, we utilised the *Nptn^{tm1b}* mouse mutant generated as part of the International Mouse
118 Phenotyping Consortium (IMPC) programme, in which both isoforms are disrupted (Fig 1A, B). As
119 NEUROPLASTIN is a highly glycosylated membrane protein, total protein lysates were first enriched for
120 the membrane fraction before treatment with PNGase F to remove N-linked glycans [8, 12]. In the whole
121 cochlear membrane-enriched fraction, the anti-pan-Np antibody detects bands for both Np65 and Np55
122 (Fig 2A), whereas the anti-Np65-specific antibody produced only a single band corresponding to Np65

123 (Fig 2A), confirming the presence of both Np55 and Np65 protein isoforms in wild type cochleae.
124 However, for mutant *Nptn*^{tm1b/tm1b} lysates, no bands were present when probing the membrane-enriched
125 fractions using either antibody (Fig 2A). These results validate the specificity of the antibodies for
126 immunoblotting and also demonstrate the absence of both NEUROPLASTIN isoforms in *Nptn*^{tm1b/tm1b}
127 cochleae. Similar results were achieved when probing brain lysates prepared from *Nptn*^{+/+} and
128 *Nptn*^{tm1b/tm1b} mice (Fig 2B). Localisation of NEUROPLASTIN protein in cochleae was also assessed
129 employing immunolabeling of cochlear cryosections. In wild type cochlear tissue, the anti-pan-Np
130 antibody produced strong labelling of outer hair cell (OHC) stereocilia, the body of inner hair cells (IHCs)
131 and spiral ganglion neurons (SGNs) (Fig 2C). The anti-Np65-specific antibody produced a signal in the
132 cell body of IHCs only (Fig 2D). In addition, both antibodies labelled the non-sensory cells lateral to the
133 OHCs, with the anti-pan-Np antibody showing diffuse membrane labelling, and the anti-Np65 antibody
134 labelling the basal region of these cells (Fig 2C, D), which are presumed to be Hensen and Boettcher
135 cells. Neither antibody labelled cochlear tissue derived from *Nptn*^{tm1b/tm1b} mutants (Fig 2C, D). Although
136 Np55 is preferentially localised in the stereocilia of OHCs and in SGNs, and Np65 in IHCs, our data
137 cannot discern whether Np55 is also expressed in IHCs.

138
139 **Fig 1. Neuroplastin gene schematic and alleles.** (A) Schematic of the wild type Neuroplastin gene locus
140 consisting of eight exons that encode: three extracellular Ig domains; a transmembrane region (TM); and, a short
141 intracellular region. Alternative splicing involving the inclusion, or skipping, of exon 2 leads to the production of
142 transcripts encoding the larger Np65, or smaller Np55, protein isoform, respectively. Previously reported mutant
143 alleles *audio-1* [13] and *pitch* [12] are point mutations present in exons 3 and 6, respectively, affecting both
144 isoforms. (B) the *Nptn*^{tm1a(EUCOMM)Hmgv} (*Nptn*^{tm1a}) is a knockout first, conditional-ready allele, that was used to
145 generate both the *Nptn*^{tm1b(EUCOMM)Hmgv} (*Nptn*^{tm1b}) knockout allele lacking exons 5 and 6, and the
146 *Nptn*^{tm1c(EUCOMM)Hmgv} (*Nptn*^{fl}) floxed allele. Subsequent exposure of the *Nptn*^{fl} allele to cre recombinase excises
147 exons 5 and 6, resulting in a null allele (*Nptn*^{tm1d}) in cells expressing *cre*. (C) An isoform-specific Np65 knockout
148 mutant (*Nptn*^{Δexon2}) was generated using CRISPR/Cas9-mediated deletion of 941 nucleotides encompassing exon
149 2. Mice homozygous for the *Nptn*^{Δexon2} are unable to express the larger Np65 isoform, while expression of Np55
150 remains.

151

152 **Fig 2. Np65 and Np55 are cochlear expressed.** (A) Western blot of membrane-enriched fractions prepared from
153 *Nptn*^{+/+} and *Nptn*^{tm1b/tm1b} cochleae. Lysates were treated with PNGase F to remove N-linked glycans before
154 separation. In the wild type membrane fraction, the anti-pan-Np antibody detects bands corresponding to native
155 Np65 (44.4 kDa) and Np55 (31.3 kDa), whereas the anti-Np65-specific antibody detects only a single band
156 corresponding to Np65. No bands were detected in the membrane fraction prepared from *Nptn*^{tm1b/tm1b} cochleae
157 using either antibody. Na⁺/K⁺-ATPase was used as a marker protein for the plasma membrane. (B) Whole brain
158 protein lysates prepared from *Nptn*^{tm1b/tm1b} (*tm1b/tm1b*), *Nptn*^{Δexon2/Δexon2} (*Δ2/Δ2*) and their respective wild type
159 controls, were separated by PAGE and Western blotted utilizing an anti-pan-Np antibody and an anti-Np65
160 antibody. For wild type lysates, both Np55 and Np65 are detected. However, neither protein isoform was detected
161 in *Nptn*^{tm1b/tm1b} lysates. Importantly, only Np55 was detected in *Nptn*^{Δexon2/Δexon2} lysates, confirming the absence of
162 Np65. Western blots were run using native (untreated) and deglycosylated (PNGase F) lysates. Tubulin is used
163 as a loading control. (C) Cochlear immunohistochemistry of cryosections using the anti-pan-Np antibody showed
164 labelling of outer hair cell (OHC) stereocilia, inner hair cells (IHC), support cells lateral to the hair cells, and the
165 spiral ganglion neurons (SGN). No signal was observed in *Nptn*^{tm1b/tm1b} cochlea. (D) The anti-Np65 specific
166 antibody showed labelling of IHCs and support cells lateral to the hair cells. No signal was observed in *Nptn*^{tm1b/tm1b}
167 cochleae. Scale = 20 μm. (E) ABR threshold measures recorded from 1-month old mice showing profoundly
168 elevated thresholds for all stimuli tested in *Nptn*^{tm1b/tm1b} mice (red triangles, n = 8) compared to wild type littermates
169 (black circle, n = 5). Heterozygous *Nptn*^{+/tm1b} mice (blue squares, n = 5) exhibit a significant high frequency (≥12
170 kHz) hearing loss compared to control littermates. Data shown as median ± I.Q.R with individual data points. One-
171 way ANOVA comparing to wild type, employing Dunnett's test for multiple comparisons. (F) Average DPOAE
172 responses recorded from 1-month old mice. Both *Nptn*^{tm1b/tm1b} (n = 10) and *Nptn*^{+/tm1b} (n = 5) mice have suppressed
173 response amplitudes compared to littermate controls (n = 7). Data are mean ± SD with individual data points
174 shown. One-way ANOVA comparing to wild type controls, employing Dunnett's test for multiple comparisons.

175

176 IMPC-based auditory phenotyping of four *Nptn*^{tm1b/tm1b} mice identified this mutation as a
177 candidate hearing loss allele [11]. However, due to the high-throughput nature of the IMPC programme,
178 no further study of their auditory function was undertaken. To test the consequence of the *Nptn*^{tm1b} allele
179 upon hearing function, heterozygous intercross matings were set up and the resultant offspring subject

180 to auditory phenotyping. At four weeks of age, homozygous *Nptn*^{tm1b/tm1b} mutants are profoundly deaf
181 with ABR-threshold values ≥ 70 dB SPL across all frequencies tested, with many of these mice having
182 no evoked ABR response up to 95 dB SPL at one or more frequencies (Fig 2E). In contrast, age-
183 matched wild-type *Nptn*^{+/+} littermate mice exhibit ABR-threshold values within the expected normal
184 range for each of the frequencies tested (between 20 - 55 dB SPL). In contrast to previously reported
185 *Nptn* models [12, 13], heterozygous *Nptn*^{+tm1b} littermate mice exhibit significantly elevated mean ABR-
186 thresholds for higher frequency stimuli (≥ 18 kHz, $P < 0.001$, one-way ANOVA) (Fig 2E).

187 Together, these data show that Np65 and Np55 are both present in wild type cochlear tissue,
188 although they exhibit differential patterns of cellular expression. Furthermore, we confirm the *Nptn*^{tm1b}
189 allele is a null that causes hearing loss, which is consistent with previous studies showing that *Nptn*
190 loss-of-function mutations cause recessive deafness [12, 13]. However, our finding that heterozygous
191 *Nptn*^{+tm1b} mutant mice exhibit high-frequency hearing impairment is an important new finding, which
192 impacts upon the interpretation of *NPTN* variants identified in humans with hearing loss.

193

194 **Loss of NEUROPLASTIN affects the functional maturation of OHCs**

195 Our immunolabeling data show the localisation of Np55 in OHC stereocilia bundles (Fig. 1D). To
196 determine if OHC activity is affected in the absence of NEUROPLASTIN we recorded distortion-product
197 otoacoustic emissions (DPOAEs), which are an *in vivo* measure of OHC function. At 5-weeks of age,
198 DPOAEs are significantly reduced in *Nptn*^{tm1b/tm1b} mice at all frequencies tested compared to *Nptn*^{+/+}
199 littermates (Fig 2F), indicating that OHC function is likely impaired in *Nptn*^{tm1b/tm1b} mutant mice. In
200 correlation to the ABR data, *Nptn*^{+tm1b} mice show a decrease in their DPOAE response to higher
201 frequency stimuli (≥ 12 kHz, $P < 0.001$, one-way ANOVA) (Fig 2F).

202 Since Np55 is expressed at the OHC stereocilia, we investigated the ability of *Nptn*^{tm1b} mice to
203 elicit mechano-electrical transducer (MET) currents from P7 and P8 OHCs (Fig 3A-H) by displacing their
204 hair bundles in the excitatory and inhibitory direction using a piezo-driven fluid-jet [2, 16]. This age range
205 was selected because it is a time when MET recordings are very reliable and the MET current has

206 reached a mature-like size [17]. At hyperpolarized membrane potentials, the displacement of the hair
207 bundle in the excitatory direction (i.e. towards the taller stereocilia) of P8 OHCs elicited an inward MET
208 current from both *Nptn*^{+/*tm1b*} (Fig 3A) and *Nptn*^{*tm1b/tm1b*} mice (Fig 3B). The maximal MET current in
209 *Nptn*^{*tm1b/tm1b*} P8 OHCs (-1219 ± 138 pA $n = 9$) was significantly reduced compared to that recorded in
210 *Nptn*^{+/*tm1b*} P8 OHCs (-1622 ± 194 pA at -124 mV, $n = 14$, $P < 0.0001$, t -test, Fig 3C,E). However, just a
211 day earlier, at P7, the maximum MET current was not significantly different between the genotypes (P
212 $= 0.7743$, one-way ANOVA, Fig 3D, E). Because the MET current reverses near 0 mV, it becomes
213 outward when excitatory bundle displacements are applied during voltage steps positive to its reversal
214 potential (Fig 3A-D). At P8, but not at P7, the maximum MET current was significantly reduced in
215 *Nptn*^{*tm1b/tm1b*} compared to that recorded in *Nptn*^{+/*tm1b*} (P8: $P < 0.0001$, t -test; P7: $P = 0.9537$, one-way
216 ANOVA, Fig 3F).

217

218 **Fig 3. Mechanoelectrical transducer current is affected in *Nptn*^{*tm1b*} mice.** (A, B) Saturating MET currents in
219 apical OHCs from a heterozygous *Nptn*^{+/*tm1b*} (A, P8) and a homozygous knockout *Nptn*^{*tm1b/tm1b*} (B, P8) mouse in
220 response to 50 Hz sinusoidal force stimuli to the hair bundles at membrane potentials of -124 mV. Driver voltage
221 (DV) stimuli to the fluid-jet are shown above the traces (excitatory stimuli: positive deflections of the DV). The
222 arrows and arrowheads indicate the closure of the transducer channel in response to inhibitory bundle stimuli at $-$
223 124 mV and $+96$ mV, respectively. (C,D) Average peak to peak MET current-voltage curves recorded from P8 (C)
224 and P7 (D) OHCs of mice from the different genotypes indicated in the panels. Currents were obtained by stepping
225 the OHC membrane potential from -124 mV to $+96$ mV in 20 mV increments while mechanically stimulating their
226 hair bundles. (E, F) Average maximal MET current recorded at -124 mV (E) and $+96$ mV (F) from OHCs at P7 and
227 P8 of *Nptn*^{+/*tm1b*} and littermate *Nptn*^{*tm1b/tm1b*} mice. Single-data points are shown as open symbols. (G, H) Resting
228 open probability (P_o) of the MET current at the holding potential of -124 mV (G) and $+96$ mV (H) measured from
229 P7 and P8 OHCs of both genotypes. The resting current is given by the holding current minus the current present
230 during inhibitory bundle deflection. Data are mean \pm SD.

231

232 The resting open probability (P_o) of the MET channel, which is defined by the resting MET current
233 flowing through open MET channels in the absence of mechanical stimulation, can be measured from

234 the difference between the holding current and the current present during inhibitory bundle deflection
235 (MET channel closed). At negative membrane potentials (-124 mV), the resting current (Fig. 3A,B,
236 arrows) was present in OHCs and was not significantly different at both P7 ($P = 0.6316$, one-way
237 ANOVA) and P8 ($P = 0.5263$, t -test) (Fig 3G). At positive potentials (+96 mV), the MET channels showed
238 a larger resting transducer current (Fig 3A, B, arrowheads), which is due to an increased open probability
239 of the transducer channel, resulting from a reduced driving force for Ca^{2+} influx [2, 17, 18]. This larger
240 resting MET open probability at +96 mV was significantly reduced between $Nptn^{+/tm1b}$ and $Nptn^{tm1b/tm1b}$
241 OHCs at P8 ($P = 0.0006$, t -test) and between both $Nptn^{+/tm1b}$ and $Nptn^{tm1b/tm1b}$ and wild type OHCs at P7
242 ($P = 0.0201$, one-way ANOVA) (Fig 3H). These data imply that the reduced expression or absence of
243 NEUROPLASTIN caused a reduction in the size and resting MET current in OHCs starting from about
244 P8.

245 We then investigated whether the absence of NEUROPLASTIN caused any additional
246 phenotype in the basolateral membrane of the OHCs since it was also expressed in their cell body.
247 Immature OHCs express a delayed rectifier K^+ current, named I_K [19], which was present in all mice
248 investigated, irrespective of genotype (Fig 4A-D). The size of the steady-state K^+ current, measured at
249 0 mV, did not change significantly between $Nptn^{+/+}$ (3.16 ± 1.0 nA, $n = 5$), $Nptn^{+/tm1b}$ (3.50 ± 0.9 nA, $n =$
250 7) and $Nptn^{tm1b/tm1b}$ (2.95 ± 0.5 nA, $n = 6$) OHCs ($P = 0.5051$, one-way ANOVA). At the onset of function
251 (~P8: [19]), OHCs start to down-regulate the immature I_K and instead up-regulate their adult-like K^+
252 current, named $I_{K,n}$, which is carried by KCNQ4 channels. The size and time-course of $I_{K,n}$ in the OHCs
253 from heterozygous mice (Fig 4E, F) were indistinguishable from that previously reported in wild type
254 mice [19, 20]. However, in age-matched $Nptn^{tm1b/tm1b}$ mice, while I_K was no longer present in mature
255 OHCs, the size of the $I_{K,n}$ current was significantly reduced compared to that measured in $Nptn^{+/tm1b}$ mice
256 ($P < 0.0001$, Fig 4E-G). These findings indicate that although OHCs from $Nptn^{tm1b/tm1b}$ mice are initially
257 able to develop toward mature mechano-sensory receptors, the level of expression of their characteristic
258 basolateral K^+ current $I_{K,n}$ remained very low, which indicates that OHCs were unable to reach full
259 maturity.

260 The abnormal MET current and reduced $I_{K,n}$ in OHCs from $Nptn^{tm1b/tm1b}$ mice would largely impact their
261 ability to generate physiological receptor potentials, thus explaining the loss of DPOAEs (Fig 1F).

262

263 **Fig 4. The development of OHCs is disrupted in $Nptn^{tm1b}$ mice.** (A-C) Current responses from OHCs of control
264 (A: $Nptn^{+/+}$) heterozygous (B: $Nptn^{+/tm1b}$) and homozygous (C: $Nptn^{tm1b/tm1b}$) mice at P7, which is during pre-hearing
265 ages. Current recordings were elicited by using depolarising and hyperpolarising voltage steps (10 mV increments)
266 from the holding potential of -84 mV to the various test potentials shown by some of the traces. (D) Steady-state
267 current-voltage curves obtained from P7 OHCs from the three genotypes. (E) Current responses from mature
268 OHCs of $Nptn^{+/tm1b}$ (left) and $Nptn^{tm1b/tm1b}$ (right) mice at P16. Note that the time-course of the currents are
269 comparable between the two genotypes, although the current is largely reduced in the $Nptn^{tm1b/tm1b}$ mouse. (F)
270 Steady-state current-voltage curves obtained from P16 OHCs from the two genotypes. (G, H) Size of $I_{K,n}$ measured
271 as the difference between the peak and steady-state of the deactivating inward current at -124 mV [19]. The
272 number of IHCs recorded are shown above each column. Average data are plotted as mean \pm SD.

273

274 **NEUROPLASTIN is required for normal IHC development**

275 Considering the substantial hearing loss observed in young-adult $Nptn^{tm1b/tm1b}$ mice (Fig 2E, F),
276 and the finding that Np65 (and possibly Np55) is expressed in the basolateral region of the IHCs, we
277 investigated whether the absence of NEUROPLASTIN had any role in their normal function (Fig 5A-G).
278 We found that mature IHCs expressed a large outward K^+ current, which was present in both $Nptn^{+/+}$
279 and $Nptn^{+/tm1b}$ mice (Fig. 5A, D), but was largely reduced in $Nptn^{tm1b/tm1b}$ mice (Fig 5B, D). A characteristic
280 K^+ current of mature IHCs is the rapid activating, large conductance Ca^{2+} -activated K^+ current carried
281 by BK channels, named $I_{K,f}$ [17, 21, 22]. $I_{K,f}$ was present in IHCs from $Nptn^{+/+}$ and $Nptn^{+/tm1b}$ mice, but
282 absent in $Nptn^{tm1b/tm1b}$ mice (Fig 5A-C). The size of the total outward K^+ current I_K and the isolated $I_{K,f}$
283 was significantly reduced between the IHCs of $Nptn^{+/+}$ and $Nptn^{+/tm1b}$ mice and those from $Nptn^{tm1b/tm1b}$
284 mice (I_K : $P = 0.0099$, Fig 5E; $I_{K,f}$: $P < 0.0001$, Fig 5F, one-way ANOVA). Similar to OHCs, mature IHCs
285 also express $I_{K,n}$ [23, 24]. In IHCs from $Nptn^{tm1b/tm1b}$ mice, we observed a very small inward current that
286 could be attributed to $I_{K,n}$ (Fig 4G), which was significantly reduced compared to that from IHCs of

287 *Nptn*^{+/*tm1b*} mice ($P = 0.0007$, Fig 5G, one-way ANOVA). However, this current could also be a remnant
288 of the immature inward current $I_{K,1}$ [25], since IHCs seem to retain all features of immature cells. This
289 indicates that different from OHCs, the development of IHCs from *Nptn*^{*tm1b/tm1b*} mice appears to be stuck
290 at immature stages.

291

292 **Fig 5. NEUROPLASTIN is required for normal IHC maturation.** (A, B) Current responses from IHCs of
293 heterozygous (A: *Nptn*^{+/*tm1b*}, P18) and homozygous (B: *Nptn*^{*tm1b/tm1b*}, P19) mice, which is after hearing onset at
294 P12. Current recordings were elicited by using depolarising and hyperpolarising voltage steps (10 mV increments)
295 from the holding potential of -84 mV to the various test potentials shown by some of the traces. (C) An expanded
296 version of the first 10 ms of the current traces from panels A and B, which emphasises the presence of the rapidly
297 activating $I_{K,f}$. (D) Steady-state current-voltage curves obtained from P18-P25 IHCs from the three genotypes. (E-
298 G) Size of the total outward K^+ current I_K (E), the isolated $I_{K,f}$ (F) and $I_{K,n}$ (G). The size of $I_{K,f}$ was measured at -25
299 mV and 1 ms from the onset of the voltage step [22]. The size of $I_{K,n}$ was measured as the difference between the
300 peak and steady-state of the deactivating inward current at -124 mV [19]. The number of IHCs recorded are shown
301 above each column. Average data are plotted as mean \pm SD.

302

303 Previous studies have demonstrated synaptic defects in NEUROPLASTIN deficient mice
304 (*Nptn*^{*pitch*}, [12]). To assess synaptic coupling between IHCs and afferent SGNs in *Nptn*^{*tm1b*} mice, we
305 performed whole-mount immunolabeling of cochleae, using an anti-Ribeye antibody (pre-synaptic
306 ribbon) and an anti-GluR2 antibody (post-synaptic density) (Fig 6A). In the mid-apical region, *Nptn*^{+/*tm1b*}
307 cochleae were found to have similar numbers of matched and unmatched synapses to wild type
308 cochleae, whereas *Nptn*^{*tm1b/tm1b*} cochleae were found to exhibit a $49.0 \pm 13.6\%$ reduction in the number
309 of matched pre- and post-synaptic puncta compared to wild type littermates ($P < 0.0001$, $n = 3$ mice, 30
310 cells in both genotypes, unpaired t -tests with Holm-Sidak correction, Fig 6B). Total counts of Ribeye
311 puncta show that the reduction in matched synapses corresponded to a $44.9 \pm 11.5\%$ decrease in the
312 number of IHC ribbons ($P < 0.001$, $n = 3$ mice, 30 cells in both genotypes, Fig 6B), suggesting it is loss
313 of the pre-synaptic component that underlies the reduction in matched synapses. To investigate whether
314 a reduction in the number of ribbon synapses may underlie the high-frequency hearing loss exhibited

315 by *Nptn*^{+/*tm1b*} mice (Fig 2E), basal IHC synapses were also assessed. Interestingly, while there was a
316 small decrease in the number of unmatched GluR2 and Ribeye puncta, there was no significant
317 difference in the number of matched synapses when compared with wild type (Fig 6C, D). This suggests
318 that an overt synaptic deficit does not underlie the high-frequency hearing impairment exhibited by the
319 *Nptn*^{+/*tm1b*} mice.

320

321 **Fig 6. Heterozygous *Nptn*^{+/*tm1b*} mice exhibit reduced ABR wave I amplitudes and increased latencies.**

322 (A) Maximum intensity projections of whole-mount mid-apical cochleae from *Nptn*^{+/*+*}, *Nptn*^{+/*tm1b*}, and *Nptn*^{*tm1b/tm1b*}
323 mice labelled with the pre-synaptic ribbon marker Ribeye (red) and post-synaptic density marker GluR2/3 (cyan).
324 (B) Counts of Ribeye and GluR2/3 puncta were made from ten mid-apical IHCs from *Nptn*^{+/*+*} (black), *Nptn*^{+/*tm1b*}
325 (blue) and *Nptn*^{*tm1b/tm1b*} (red) cochleae (two independent regions per mouse, three mice per genotype). Ribeye and
326 GluR2/3 puncta were considered matched when directly juxtaposed to one another. A larger number of unmatched
327 GluR2/3 puncta and fewer Ribeye puncta were observed in *Nptn*^{*tm1b/tm1b*} cochleae. (C) Maximum intensity
328 projections of whole-mount basal cochleae from *Nptn*^{+/*+*} and *Nptn*^{+/*tm1b*} mice labelled with the pre-synaptic ribbon
329 marker Ribeye (red) and post-synaptic density marker GluR2/3 (cyan). (D) Counts of Ribeye and GluR2/3 puncta
330 were made from 5-10 IHCs from *Nptn*^{+/*+*} (black) and *Nptn*^{+/*tm1b*} (blue) cochleae (two independent regions per
331 mouse, three mice per genotype). *Nptn*^{+/*tm1b*} mice show a decrease in the number of unmatched GluR2/3 puncta
332 compared with *Nptn*^{+/*+*}. Insets are an enlarged view of a 5 µm x 5 µm region highlighted by the dashed box in the
333 corresponding above image. Scale bar = 5 µm. Data are mean ± SD with individual data points shown. Data are
334 compared against wild type controls using unpaired t-tests with a Holm-Sidak correction for multiple comparisons.
335 (E) Averaged ABR wave I in response to a click stimulus recorded at 30 dB above hearing threshold for *Nptn*^{+/*tm1b*}
336 (blue line, n = 5) and *Nptn*^{+/*+*} (black line, n = 5) mice. Across all intensities, *Nptn*^{+/*tm1b*} mice had reduced amplitudes
337 (F) and increased latencies (G) compared with *Nptn*^{+/*+*} mice. Data are mean ± SD with individual data points
338 shown. Analysed using a two-way ANOVA.

339

340 To further interrogate the ABR phenotype exhibited by heterozygous *Nptn*^{+/*tm1b*} mice, we
341 examined their recorded ABR waveforms, which represent the sound stimuli-evoked electrical activity
342 in the auditory nerve and brainstem nuclei. In response to the broadband click stimulus, *Nptn*^{+/*tm1b*} mice

343 did not show an overt hearing threshold increase (Fig 2E). However, they do exhibit deficits in ABR
344 Wave I, which reflects the magnitude and synchronicity of activity in the primary afferent neurons. In
345 particular, *Nptn*^{+/*tm1b*} mice show reduced amplitudes ($P < 0.0001$, $n = 5$ for both genotypes, two-way
346 ANOVA) and slower onset to peak ($P = 0.0002$, $n = 5$ for both genotypes, two-way ANOVA) compared
347 to *Nptn*^{+/+} littermate mice (Fig 6E-G).

348

349 **Cochlear hair cell expression of NEUROPLASTIN is essential for hearing**

350 To determine if Neuroplastin expression in cochlear hair cells is essential for hearing, we utilised
351 a floxed *Nptn* allele (*Nptn*^{fl}) (Fig 1) crossed with a *Myo15-cre* driver mouse line. This conditional knockout
352 mouse (*Nptn*^{fl/fl};*Myo15-cre*⁺) allowed us to delete *Nptn* specifically in both OHCs and IHCs from
353 approximately P4 onwards [26], which is several days prior to hair cell functional maturation for OHCs
354 (~P8) and IHCs (~P12). Immunolabeling of cochleae from *Nptn*^{fl/fl};*Myo15-cre*⁺ mice confirmed the
355 absence of NEUROPLASTIN in both OHCs and IHCs. However, labelling remained present adjacent to
356 the basal region of IHCs (Fig 7A). Co-labelling with Neurofilament-200K (NF200) indicates that this
357 labelling is associated with NEUROPLASTIN localisation in post-synaptic SGN afferent fibres (Fig 7B).
358 This is consistent with our wild type cochleae immunolabeling data, as well as available scRNA-seq
359 data suggesting *Nptn* transcripts are present in SGNs and HCs (umgear.org).

360

361 **Fig 7. Hair Cell-specific deletion of Neuroplastin elicits a milder auditory phenotype.**

362 (A) Maximum intensity projections of whole mount immunohistochemistry of cochleae from 1-month old mice using
363 an anti-pan-Np antibody. Neuroplastin is specifically deleted from both IHCs and OHCs in *Myo15-cre*⁺ cochleae.
364 Staining for NEUROPLASTIN is still present around the base of IHCs. (B) Co-labelling with anti-Neurofilament
365 200K (NF200) in *Nptn*^{fl/fl};*Myo15-cre*⁺ cochleae. Overlap (right) shows regions in which signals for both
366 NEUROPLASTIN and NF200 are detected, with colour indicating summed intensity of signal. Patterns of staining
367 are similar for both antibodies at the base of IHCs suggesting that NEUROPLASTIN labelling is associated with
368 spiral ganglion fibres. Scale bar = 10 μ m. (C) ABR threshold measures for *Myo15-cre*⁺ mice at 1-month of age
369 shows elevated thresholds in *Nptn*^{fl/fl};*Myo15-cre*⁺ mice (red triangles, $n = 5$) compared to *Nptn*^{+/+};*Myo15-cre*⁺ mice

370 (black circles, n = 5). Heterozygous *Nptn^{fl/fl};Myo15-cre⁺* mice (blue squares, n = 5) also exhibit raised thresholds
371 at ≥ 24 kHz compared with controls. Data are median \pm IQR with individual data points shown. One-way ANOVA
372 comparing against wild type using Dunnett's test for multiple comparisons. (D) Average DPOAE responses of
373 *Nptn^{fl/fl};Myo15-cre⁻* (black circles, n = 10) and *Nptn^{fl/fl};Myo15-cre⁺* (red triangles, n = 7) mice at 1-month of age.
374 Data are mean \pm SD with individual data points shown. One-way ANOVA comparing against wild type controls
375 using Dunnett's test for multiple comparisons. (E-F) Click-evoked ABR wave I measures comparing *Nptn^{+/fl};Myo15-
376 cre⁺* with *Nptn^{+/+};Myo15-cre⁺* mice. Waveforms were not significantly different. Amplitude: P = 0.1597, Latency: P
377 = 0.4229 (two-way ANOVA). Inset shows an average of wave I following click stimulus at 30 dB above threshold.
378 Data are mean \pm SD with individual data points shown. (G) Maximum intensity projections of mid-apical cochlear
379 whole-mounts from *Nptn^{fl/fl};Myo15-cre⁻* and *Nptn^{fl/fl};Myo15-cre⁺* mice labelled with the IHC pre-synaptic ribbon
380 marker Ribeye (red) and post-synaptic density marker GluR2/3 (cyan). Insets show an enlarged 5 μ m x 5 μ m
381 region highlighted by the dashed box in the above image. Scale bar = 5 μ m. (H) Counts of Ribeye and GluR2/3
382 puncta were made from ten adjacent hair cells (two independent regions per mouse, three mice per genotype).
383 Ribeye and GluR2/3 were considered matched when directly juxtaposed to one and other. No significant difference
384 was found in the total numbers of Ribeye or GluR2 puncta, or matched Ribeye/GluR2 puncta. Data are mean \pm
385 SD with individual data points shown. Data compared against wild type controls using unpaired t-tests with a Holm-
386 Sidak correction for multiple comparisons.

387

388 At four weeks of age, *Nptn^{fl/fl}* mice without the cre-driver (*Myo15-cre⁻*) exhibit ABR thresholds
389 similar to those of wild type (*Nptn^{+/+};Myo15-cre⁻*) littermate mice (S1 Fig) demonstrating the floxed allele
390 does not affect hearing. Similarly, wild type mice carrying the *Myo15-Cre* (*Nptn^{+/+};Myo15-cre⁺*) have
391 normal ABR thresholds (S1 Fig). However, when Neuroplastin is specifically deleted in hair cells
392 (*Nptn^{fl/fl};Myo15-cre⁺*), ABR thresholds are significantly raised (P < 0.0001, one-way ANOVA) to between
393 65 – 90 dB SPL (Fig 7C), and DPOAEs are reduced across most of the tested frequencies (Fig 7D).
394 Interestingly, the auditory deficit is milder than that exhibited by the global *Neuroplastin* knockout
395 (*Nptn^{tm1b/tm1b}*) mice, with no *Nptn^{fl/fl};Myo15-cre⁺* mouse exhibiting an evoked ABR response of >90 dB
396 SPL (NR) at any frequency tested. Similarly, *Nptn^{+/fl};Myo15-cre⁺* mice exhibit a milder hearing loss
397 phenotype than *Nptn^{+/tm1b}* mice, with increases in threshold only found at the highest frequency tested

398 (30 kHz, Fig 7C, range: 55 – 80 dB SPL, $P < 0.0001$, one-way ANOVA). However, in contrast to *Nptn^{+tm1b}*
399 mice, *Nptn^{fl/fl};Myo15-cre⁺* mice do not show any differences in the amplitude or latency of ABR wave I
400 following a click stimulus (Fig 7E,F).

401 Given the continued presence of NEUROPLASTIN at the post-synaptic region, and slightly
402 milder ABR phenotype in *Nptn^{fl/fl};Myo15-cre⁺* mice, we next assessed numbers of Ribeye and GluR2
403 puncta present in these mice compared with normal hearing *Nptn^{fl/fl};Myo15-cre⁻* mice. No significant
404 difference in the total numbers of Ribeye or GluR2 puncta, or matched Ribeye/GluR2 puncta, were
405 found (Fig 7G, H).

406 Together, these data show that hair cell expression of *Nptn* is essential for normal hearing
407 function, and suggest that presence of NEUROPLASTIN at the post-synapse, and in the developing
408 HCs up to ~P4, is sufficient to support IHC afferent innervation and ribbon synapse formation.

409

410 **Neuroplastin-65 is not required for hearing function**

411 Our finding that *Nptn^{tm1b/tm1b}* mice (constitutive null for Np55 and Np65) exhibit ribbon synapse
412 deficits, but that *Nptn^{fl/fl};Myo15-cre⁺* mice (lacking Np55 and Np65 from ~P4) have normal synapses,
413 suggests that NEUROPLASTIN is involved in IHC innervation. Indeed, in a previous paper we propose
414 that Np65 is required for the formation of mature ribbon synapses [12]. Furthermore, our immunolabeling
415 data show that Np65 is present in IHCs (Fig 2D and 8C). However, all of the *Nptn* mutant alleles studied
416 in relation to hearing to date target both Np55 and Np65. To investigate the requirement of Np65 for
417 auditory function, Np65-knockout mice were generated using a CRISPR/Cas9-mediated exon deletion
418 approach, targeting exon 2 of the *Nptn* gene (*Nptn^{Δexon2}*) that encodes the Np65-specific Ig1 domain (Fig
419 1).

420 In *Nptn^{Δexon2/Δexon2}* mice, the absence of Np65 in cochlear tissue was confirmed by Western
421 blotting, while Np55 remained present (Fig 8A). Immunolabeling of wild type (*Nptn^{+/+}*) and
422 *Nptn^{Δexon2/Δexon2}* cochleae, utilising the anti-pan-Np antibody, showed no overt changes in signal location
423 or intensity in either IHCs, OHCs, or lateral non-sensory cells (Fig 8B). NEUROPLASTIN expression

424 was also assessed using the anti-Np65-specific antibody, which labelled *Nptn*^{+/+} IHCs, but was absent
425 from *Nptn*^{Δexon2/Δexon2} IHCs (Fig 8C), thus confirming the successful deletion of Np65 in these mice. ABR
426 recordings showed that at 4-weeks of age *Nptn*^{Δexon2/Δexon2} mice have thresholds within the typically
427 normal range (Fig 8D, *Nptn*^{Δexon2/Δexon2}: range 15-65 dB SPL, n = 4; *Nptn*^{+/+}: range 15-60 dB SPL, n = 5),
428 and their DPOAE responses were also indistinguishable from control littermates (Fig 8E). Furthermore,
429 examination of their ABR waveforms in response to a broadband click stimulus showed no overt deficits
430 in the magnitude and synchronicity of activity in primary afferent neurons (Fig 8F, G). We also assessed
431 IHC ribbon synapses in 3-week old *Nptn*^{Δexon2/Δexon2} mice, and found no significant differences in their
432 numbers (Fig 8H, I). To assess whether Np65-null mice exhibit a late-onset progressive hearing
433 impairment, the *Nptn*^{Δexon2} allele was first crossed onto a *Cdh23*-repaired C57BL/6N background to
434 circumvent interference from the age-related deafness-causing strain-specific *Cdh23*^{ahl} allele [27]. No
435 declines in hearing thresholds were observed up to 6-months of age (Fig 9A-B), and DPOAE responses
436 were comparable over the same time scale (Fig 9C). Together these data suggest that the
437 NEUROPLASTIN isoform Np65 has a redundant role in the establishment and maintenance of
438 mammalian hearing and that Np55 alone is sufficient for auditory function.

439

440 **Fig 8. Np65 is not essential for hearing.** (A) Western blot of membrane-enriched fractions from *Nptn*^{+/+} (+/+) and
441 *Nptn*^{Δexon2/Δexon2} (Δ2/Δ2) cochlear lysates. Lysates were treated with PNGase F to remove N-linked glycans prior to
442 running. The anti-pan-Np antibody detects bands corresponding to Np65 and Np55 in the wild type membrane
443 fraction and the anti-Np65-specific antibody detects a single band corresponding to Np65. No bands were detected
444 in *Nptn*^{tm1b/tm1b} lysates when using either antibody. Na⁺/K⁺-ATPase was used as a plasma membrane marker
445 protein. (B) Immunohistochemistry using anti-pan-Np on cochlear cryosections showed labelling of outer hair cell
446 (OHC) stereocilia, the inner hair cells (IHCs), and lateral support cells in both *Nptn*^{+/+} and *Nptn*^{Δexon2/Δexon2} cochleae.
447 (C) the anti-Np65 specific antibody showed labelling of IHCs in *Nptn*^{+/+} cochleae. No signal was observed in
448 *Nptn*^{Δexon2/Δexon2} cochleae. Scale = 20 μm. (D) ABR threshold measures of 1-month old mice. *Nptn*^{Δexon2/Δexon2} (red
449 triangle, n = 4) and *Nptn*^{+/Δexon2} (blue square, n = 6) mice have thresholds similar to *Nptn*^{+/+} littermate controls
450 (black circle, n = 5) across all measured frequencies. Data are median ± IQR with individual data points shown.
451 One-way ANOVA comparing against wild type controls with Dunnett's correction for multiple comparisons. (E)

452 Average DPOAE responses at 1-month of age showing no significant difference between *Nptn* ^{Δ exon2/ Δ exon2} (n = 4)
453 and littermate controls (*Nptn*^{+/+}, n = 3). Data are mean \pm SD with individual data points shown. One-way ANOVA
454 comparing against wild type controls using Dunnett's test for multiple comparisons. (F-G) Click-evoked ABR wave
455 I measures comparing *Nptn*^{+/+} (black, n = 5) and *Nptn* ^{Δ exon2/ Δ exon2} (red, n = 4) mice. Waveforms were not significantly
456 different. Amplitude: P = 0.9539, Latency: P = 0.3795 (two-way ANOVA). Inset shows an average of wave I
457 following click stimulus at 30 dB above threshold. Data are mean \pm SD with individual data points shown. (H)
458 Maximum intensity projections of mid-apical cochlear whole-mounts from *Nptn* ^{Δ exon2} mice labelled with the pre-
459 synaptic ribbon marker Ribeye (red) and post-synaptic density marker GluR2/3 (cyan). Insets show an enlarged 5
460 μ m x 5 μ m region highlighted by the dashed box in the above image. Scale bar = 5 μ m. (I) Ribeye and GluR2/3
461 puncta count from ten hair cells (two independent regions per mouse, three mice per genotype). Ribeye and
462 GluR2/3 were considered matched when directly juxtaposed to one another. No significant difference was found
463 in *Nptn* ^{Δ exon2/ Δ exon2} cochleae. Data are mean \pm SD with individual data points shown. Data compared against wild
464 type controls using unpaired t-tests with a Holm-Sidak correction for multiple comparisons.

465

466 **Fig 9. Np65-null mice maintain normal hearing up to 6-months of age.** The *Nptn* ^{Δ exon2} allele was crossed onto
467 the *Cdh23*-repaired C57BL/6N background to circumvent interference from the strain-specific *Cdh23* age-related
468 hearing loss (*Cdh23*^{ahl}) allele, and ABR thresholds were tested longitudinally at (A) 1-month and (B) 6-months of
469 age. At each timepoint, the three genotype groups had similar thresholds and were within the expected normal
470 range for the frequencies tested. Data are median \pm IQR with individual data points shown. The number of
471 individual mice in each genotype group are shown in brackets. One-way ANOVA comparing against wild type with
472 Dunnett's correction for multiple comparisons. (C) DPOAE responses of Np65-null (*Nptn* ^{Δ exon2/ Δ exon2}) mice at 6-
473 months of age are comparable to age-matched wild type littermates. Data are mean \pm SD. One-way ANOVA
474 comparing against wild type littermate controls using Dunnett's test for multiple comparisons.

475

476 **OHC-expressed NEUROPLASTIN is required for PMCA2 localisation to** 477 **stereocilia**

478 Recently, NEUROPLASTIN has been reported to be an obligatory subunit to Plasma Membrane
479 Calcium ATPase (PMCA) proteins, with NEUROPLASTIN being essential for their correct localisation

480 to membranes [28]. Moreover, it was shown *in vitro* that the transmembrane domain of NEUROPLASTIN
481 alone is sufficient to drive the localisation of PMCA to the membrane [28]. In the auditory system,
482 PMCA2 and PMCA1 are both important for hair cell calcium homeostasis by extruding cytoplasmic Ca²⁺
483 ions into the extracellular fluid. PMCA2 is expressed abundantly in OHC stereocilia, while PMCA1 is
484 localized to the lateral and basolateral membrane of IHCs [29]. Using immunolabeling of wholmount
485 wild type cochleae, we also find PMCA2 and PMCA1 labelling at these locations, as well as in the lateral
486 non-sensory cells (Fig 10A). However, in *Nptn^{tm1b/tm1b}* mutants, PMCA immunoreactivity in IHCs, OHCs
487 and non-sensory cells was markedly reduced, although not completely absent (Fig 10B), which
488 corresponds to a reduction of both PMCA2 and PMCA1 (Fig 10A). However, there was no evidence of
489 reduced PMCA immunoreactivity in *Nptn^{Δexon2/Δexon2}* cochleae (Fig 10C).

490

491 **Fig 10. Hearing impairment is inversely correlated with Nptn-dependent localisation of PMCA in outer hair**

492 **cell stereocilia.** (A) Immunolabelling of cochlear cryosections using anti-PMCA1 and anti-PMCA2 antibodies. In

493 wild type tissue, PMCA1 is predominantly localised to the membrane of IHCs and OHCs, whereas PMCA2 is

494 localised to OHC stereocilia and lateral supporting cells. Labelling of the PMCA at these locations was

495 substantially reduced in *Nptn^{tm1b/tm1b}* cochleae. Scale = 20 μm. (B) The anti-pan-PMCA antibody detects PMCA1-4.

496 Maximum intensity projections of whole-mount cochlear immunolabelling using the anti-pan-PMCA antibody

497 showed labelling of OHC stereocilia and membrane of IHCs in *Nptn^{+/+}* mice, which were substantially reduced, but

498 not absent, in *Nptn^{tm1b/tm1b}* cochleae. (C) Using the anti-pan-PMCA antibody, no labelling differences were seen in

499 *Nptn^{Δexon2/Δexon2}* cochleae compared to wild-type. Scale = 10 μm. (D) ABR threshold and DPOAE response

500 measures from two *Nptn^{fl/fl};Prestin-CreER^{T2}+* mice following tamoxifen-induced cre-mediated recombination, with

501 corresponding anti-pan-Np and anti-pan-PMCA immunolabelled mid-apical cochlear whole mounts (maximum

502 intensity projections). Data from the individual mice are shown (red triangles) compared against wild type controls

503 (black circles, mean ± SD). Due to varying levels of induction, the auditory phenotype exhibited was variable with

504 some mice showing no significant phenotype (e.g. individual 1), while others showed increased ABR thresholds

505 and a decreased DPOAE response (e.g. individual 2). The auditory phenotype was directly correlated to the level

506 of *Nptn* recombination as demonstrated by immunolabelling using the anti-pan-Np antibody. Bundles that were

507 strongly stained for NEUROPLASTIN also had strong labelling for anti-pan-PMCA antibody (arrowhead), whereas
508 absent NEUROPLASTIN was correlated with a weak PMCA signal (*).

509

510 To further examine the requirement of NEUROPLASTIN for the localisation of PMCA2 in OHCs,
511 we generated *Nptn^{fl/fl};Prestin-CreER^{T2}* mice, and induced cre-mediated recombination specifically in
512 OHCs through tamoxifen delivery at 4-weeks of age. When tested by ABR and DPOAE 10-14 days
513 following tamoxifen administration, these mice were found to have a highly variable phenotype with the
514 degree of auditory deficit being directly correlated with the number of NEUROPLASTIN-negative OHCs.
515 Auditory function was not affected by the presence of the Prestin-CreER^{T2} allele or the delivery of
516 tamoxifen alone (S1 Fig). Furthermore, in *Nptn^{fl/fl};Prestin-CreER^{T2}* mice PMCA localisation was directly
517 correlated with NEUROPLASTIN expression, with NEUROPLASTIN positive OHCs showing stronger
518 labelling for PMCA in stereocilia than adjacent OHC bundles lacking NEUROPLASTIN expression (Fig
519 10D). These data are consistent with a recently published study by Lin *et al* who show reduced cochlear
520 expression of PMCA in a different *Neuroplastin* null mouse mutant (*Nptn^{tm1.2Mtg}*, [15]).
521 Our data confirm that NEUROPLASTIN is required for the correct localisation of PMCA proteins in the
522 organ of Corti, and also shows that continued expression of *Neuroplastin* in the OHCs of adult mice is
523 required to maintain hearing function.

524

525 **Neuroplastin genetically interacts with *Cdh23^{ahl}* allele in C57BL/6 mice**

526 To date, there have only been reports of recessive auditory phenotypes in *Neuroplastin* mutant
527 mice [12, 13]. However, here we observe significant high-frequency hearing loss in both *Nptn^{+/^{tm1b}}* and
528 *Nptn^{+/^{fl};Myo15-cre⁺}* mice (Fig 2E and 7C), with a corresponding reduction in DPOAEs seen when testing
529 *Nptn^{+/^{tm1b}}* mice (Fig 2F). Given we find that NEUROPLASTIN is required for localisation of PMCA2 to
530 OHC stereocilia (Fig 10), and previous studies show a genetic interaction between *Atp2b2* (encodes
531 PMCA2) mutations and the hypomorphic *Cdh23^{ahl}* allele present in the C57BL/6 background [30], we
532 tested whether the *Cdh23^{ahl}* allele is a genetic modifier of *Neuroplastin*. To enable this, we crossed the
533 *Nptn^{tm1b}* allele onto a C57BL/6N background in which the *Cdh23^{ahl}* allele has been corrected

534 (*Cdh23*^{753A>G})[27]. *Nptn*^{tm1b/tm1b} mice on the repaired C57BL/6N (*Cdh23*^{753A>G/753A>G}) background exhibit
535 a hearing phenotype comparable to *Nptn*^{tm1b/tm1b} mutants on the standard C57BL/6N (*Cdh23*^{ahl/ahl})
536 background when tested by ABR at 4-weeks, and DPOAE at 5-6 weeks (Fig 11A, B). In contrast,
537 *Nptn*^{+ /tm1b} mice on the repaired C57BL/6N background did not exhibit high-frequency hearing loss,
538 having thresholds similar to wild type control littermates (Fig 11A, B). Directly comparing hearing
539 thresholds of *Nptn*^{+ /tm1b} mice on the standard C57BL/6N background to age-matched *Nptn*^{+ /tm1b} mice on
540 the repaired C57BL/6N background, shows that on the standard background, *Nptn*^{+ /tm1b} mice have
541 significantly elevated thresholds at 18, 24, and 30 kHz ($P < 0.0001$, one-way ANOVA). Furthermore,
542 while *Nptn*^{+ /tm1b} mice maintained on a standard C57BL/6N (*Cdh23*^{ahl/ahl}) background show significant
543 deficits in click-evoked ABR wave I compared to their wild type littermates (Fig 6E-G), *Nptn*^{+ /tm1b} mice
544 maintained on the repaired C57BL/6N background do not show any wave I amplitude or latency
545 differences compared to their wild type littermates (Fig 11C, D).

546
547 **Fig 11. Neuroplastin genetically interacts with Cadherin 23.** Phenotypic measures of *Nptn*^{tm1b} mice maintained
548 on a *Cdh23*-repaired C57BL/6N (*Cdh23*^{753A>G}) background. (A) ABR threshold measurements recorded from 4-
549 week old mice. Similar to *Nptn*^{tm1b/tm1b} mice on the standard C57BL/6N genetic background, *Nptn*^{tm1b/tm1b} mice on
550 the repaired background (red triangles, $n = 6$) have profoundly elevated thresholds compared with littermate
551 *Nptn*^{+ /+} mice (black circles, $n = 5$). However, on the repaired background *Nptn*^{+ /tm1b} (blue squares, $n = 7$) have
552 thresholds indistinguishable from control mice, even at the higher frequencies. Data are median \pm IQR with
553 individual data points shown. One-way ANOVA comparing against wild type controls using Dunnett's test for
554 multiple comparisons. (B) DPOAE measurements recorded at 5-6-weeks of age. Response amplitudes were
555 significantly reduced in *Nptn*^{tm1b/tm1b} mice (red triangles, $n = 5$), whereas *Nptn*^{+ /tm1b} mice (blue squares, $n = 5$) have
556 amplitudes comparable to that of control mice (*Nptn*^{+ /+}, black circles, $n = 5$). Data are mean \pm SD with individual
557 data points shown. One-way ANOVA comparing against wild type controls using Dunnett's test for multiple
558 comparisons. (C,D) Click-evoked ABR wave I comparing *Nptn*^{+ /+} (black, $n = 5$) and *Nptn*^{+ /tm1b} (blue, $n = 7$) mice.
559 Waveforms were not significantly different. Amplitude: $P = 0.8679$, Latency: $P = 0.0568$ (two-way ANOVA). Inset
560 shows an average of wave I following a click stimulus at 30 dB above threshold. Data are mean \pm SD with individual
561 data points shown.

562

563 Our data reveal a genetic interaction between *Neuroplastin* and *Cadherin 23* (Otocadherin),
564 highlighting the importance of understanding and reporting the genetic background of mutant mouse
565 models to allow interpretation of phenotypic expressivity and reproducibility of data, respectively.

566

567 Discussion

568 The expression, localisation and function of Neuroplastin in the mammalian cochlea is a subject
569 of conflicting reports. Here, we show that both Np65 and Np55 are present in the murine cochlea and
570 that the two isoforms exhibit different patterns of cellular expression. Using a pan-Np antibody, we find
571 NEUROPLASTIN to be present in OHC stereocilia, IHC basolateral membrane, spiral ganglia, and also
572 in some lateral non-sensory cells, which is in broad agreement with previous studies [12, 13, 15]. To
573 discern the contribution to this pan-Np labelling arising from Np65, we generated a Np65-specific
574 knockout (*Nptn*^{Δexon2}) mouse model. Utilising tissues derived from these mice we were able to confirm
575 the specificity of a Np65-specific antibody, and infer localisation of Np65 at the basolateral region of
576 IHCs and some lateral non-sensory cells within wild type tissues. Importantly, no Np65 labelling was
577 observed in OHC stereocilia, supporting the findings of Zeng, et al. [13], and showing that Np55 is the
578 sole NEUROPLASTIN isoform found in these structures. Although a previous report had suggested that
579 transcripts for Np65 are present in SGNs [13], we found no evidence of the “neuron-specific” Np65 in
580 SGNs by immunolabeling (Figs 2 and 8). We had previously hypothesised that the presence of Np65 at
581 the basolateral membrane of IHCs may act to establish the afferent synapses through *trans*-homophilic
582 dimerisation across the synaptic cleft, mediated via the Np65-specific Ig1 domain. However, when Np65
583 is specifically deleted in *Nptn*^{Δexon2} mice, they showed no observable auditory phenotype, and more
584 importantly, no overt changes to the ribbon synapse count or structure (Fig 8). While we show Np65 is
585 present in wild type IHCs, and Np55 is present in IHCs of Np65 knockout (*Nptn*^{Δexon2/Δexon2}) mice, we
586 were not able to determine if Np55 is natively expressed in wild type IHCs, or if is only expressed in
587 place of Np65 in the Np65 knockout. Regardless, the lack of an auditory phenotype in homozygous

588 *Nptn*^{Δexon2} mice leads us to conclude that Np65 is functionally redundant in the mammalian cochlea.
589 Thus, we can conclude that Np65-Np65 *trans*-homophilic dimerisation is not a mechanism by which
590 afferent contacts are established and maintained at the IHC ribbon synapse. This does not exclude
591 other mechanisms by which NEUROPLASTIN could promote neurite outgrowth, such as the activation
592 of FGFR in the early development of synapses, which Np55 is capable of through cis-heterophilic
593 binding [7]. Unfortunately, given the structure of the Neuroplastin gene, we are unable to generate a
594 Np55-specific knockout and therefore are not able to determine if Np65 alone would be able support
595 auditory function.

596

597 **NEUROPLASTIN expression in hair cells is essential for hearing**

598 To investigate the requirement of NEUROPLASTIN in auditory function, we utilised the
599 *Nptn*^{tm1a(EUCOMM)Hmgu} mice that were generated as part of the IMPC programme
600 (<https://www.mousephenotype.org/>). This is a knockout-first allele that enables the generation of a
601 *Nptn*^{tm1b(EUCOMM)Hmgu} knockout allele through cre-mediated recombination (herein referred to as *Nptn*^{tm1b}),
602 or a *Nptn*^{tm1c(EUCOMM)Hmgu} conditional allele through flp-mediated recombination (herein referred to as
603 *Nptn*^{fl}) (Fig 1). Preliminary auditory phenotyping of four homozygous *Nptn*^{tm1b(EUCOMM)Hmgu} mice, at 14-
604 weeks of age, identified this as a hearing allele [11]. Using a larger cohort of mice we have validated
605 and confirmed that when homozygous the *Nptn*^{tm1b} allele results in an early-onset profound hearing loss,
606 with mice exhibiting thresholds similar to those reported for three ENU-induced mutants: *pitch* (C315S),
607 Y219X, and *audio-1* (I122N), affecting exons 6, 4, and 3, respectively [12, 13]. Furthermore, additional
608 testing of the *Nptn*^{tm1b/tm1b} mice showed that DPOAE responses were significantly reduced (Fig 2),
609 indicating OHC dysfunction as also reported for the *Nptn*^{audio-1} model [13], and an IHC synaptic deficit
610 comprising of unmatched pre- and post-synaptic markers (Fig 6), as also reported for the *Nptn*^{pitch} model
611 [12]. Interestingly, unlike previously reported *Nptn* mutant mouse models, we find an auditory phenotype
612 in heterozygous *Nptn*^{tm1b/+} mutant mice. While the phenotype is less severe than that exhibited by
613 homozygous *Nptn*^{tm1b/tm1b} mice, it does result in significantly elevated thresholds for higher frequency

614 stimuli (≥ 18 kHz) and correspondingly reduced DPOAE responses (≥ 12 kHz). A deficit was also
615 apparent in click-evoked ABR wave I amplitudes and latencies, despite no elevation of thresholds with
616 this stimulus or IHC synaptic deficits. Furthermore, utilising the floxed mice in combination with a hair
617 cell-specific cre-driver line, we show that deletion of *Nptn* in hair cells leads to elevated hearing
618 thresholds in *Nptn^{fl/fl};Myo15-cre⁺* and *Nptn^{fl/+};Myo15-cre⁺* mice, but that their hearing loss is notably
619 milder than that exhibited by aged-matched *Nptn^{tm1b/tm1b}* and *Nptn^{tm1b/+}* mice, respectively (Fig 7).
620 Moreover, also different to *Nptn^{tm1b/tm1b}* mice, *Nptn^{fl/fl};Myo15-cre⁺* mice do not exhibit an observable
621 synaptic deficit, despite having increased auditory thresholds. Taken together, our data show that the
622 expression of Neuroplastin in hair cells is essential for hearing, and suggest that expression of
623 NEUROPLASTIN in the SGNs of hair cell-specific *Nptn* knockout mice is sufficient for the establishment
624 and maintenance of IHC ribbon synapses. Interestingly, in both macaque and guinea pig, the estimated
625 contribution of OHCs to hearing thresholds as a cochlear amplifier is around 50 dB [31]. Here, threshold
626 elevations in *Nptn^{tm1b/tm1b}* mice are as high as 69 ± 6 dB (Click), while in the mutant models which do not
627 have changes to synapse structure (i.e. *Nptn^{+/-tm1b}* and *Nptn^{fl/fl};Myo15-cre⁺*) maximum threshold shifts
628 are 50 ± 10 dB (30 kHz) and 56 ± 4 dB (click), respectively. This suggests that both a reduction in OHC
629 function and disruption to IHC synapses are likely to contribute to the auditory phenotype seen in the
630 NEUROPLASTIN-null *Nptn^{tm1b/tm1b}* mice.

631 **NEUROPLASTIN is essential for hair cell mechanotransduction,** 632 **maturation and ion homeostasis**

633 Despite localisation of NEUROPLASTIN in OHC stereocilia, OHC MET currents have previously
634 been reported as unaffected in Neuroplastin loss-of-function mutants [12, 13]. However, these were
635 recorded from immature OHCs ($\leq P7$). Here, we find that OHCs of P8 *Nptn^{tm1b/tm1b}* mice have significantly
636 reduced maximal MET currents and MET channel open probability at depolarised potentials, which is
637 not evident at P7 (Fig 3). When stepping the OHC membrane potential to positive values, which is near
638 the Ca^{2+} equilibrium potential, the drive for Ca^{2+} entry into the MET channels is strongly reduced. This

639 reduced Ca^{2+} influx leads to the MET channels' increase open probability, which is a manifestation of
640 the ability of Ca^{2+} to drive adaptation and thus closing the MET channel, as demonstrated in hair cells
641 from lower vertebrates [32-34] and mouse cochleae [2]. Interestingly, we also show that *Nptn*^{tm1b/tm1b}
642 mice have significantly reduced membrane-localisation of plasma membrane Ca^{2+} ATPase (PMCA)
643 proteins across the organ of Corti (Fig. 10), which has been reported in other tissue types [35, 36] and
644 more recently in cochleae using a different NEUROPLASTIN-null mouse, *Nptn*^{tm1.2Mtg} [15]. Since the
645 expression of the Ca^{2+} pump PMCA is largely reduced at the stereocilia of OHCs from *Nptn*^{tm1b/tm1b} mice,
646 this would most likely cause Ca^{2+} to accumulate intracellularly near the MET channel during repetitive
647 bundle stimulation, leading to its adaptation and a reduced open probability compared to wild type
648 OHCs. Although MET channel recordings from PMCA knockout mice is limited, some evidence for a
649 similar reduction in the MET channel open probability has previously been obtained from newborn
650 mouse OHCs lacking the Ca^{2+} pump [37]. In addition to the defects in the MET apparatus, we find that
651 both OHCs and IHCs of *Nptn*^{tm1b/tm1b} mice fail to develop a fully mature basolateral current profile (Figs
652 4 and 5), which is in line with previous work investigating other mutations that affect
653 mechanotransduction, such as mutations in *Eps8* [38], TMC1 [39], *Pcdh15*, *Harmonin* [40] and *Cln2*
654 [41]. IHCs from *Nptn*^{tm1b/tm1b} mice retain a full pre-hearing basolateral current profile, which could be an
655 indirect consequence of impaired mechanotransduction, as seen in P8 OHCs. This is because
656 depolarising MET currents are critical for driving spontaneous action potential activity in IHCs during
657 pre-hearing stages [42], a key physiological aspect required for IHC maturation [40]. Different from IHCs,
658 OHCs from *Nptn*^{tm1b/tm1b} mice are able to mature albeit expressing a reduced K^+ current. The possible
659 mechanism linking the observed defects in the MET current and the reduced expression of $I_{\text{K,n}}$ is less
660 clear. Knockout mice for the TMC1 channel, *Eps8* and *Cln2* have abnormal OHC MET current from
661 about P8 [43], P8 [38] and P6 [41], respectively, but have opposite effects on the basolateral current
662 profile in OHCs (TMC1: no $I_{\text{K,n}}$ expression; *Eps8* and *Cln2*: normal $I_{\text{K,n}}$ expression). To further
663 investigate the requirement of NEUROPLASTIN for the localisation of PMCA proteins, we utilised a
664 tamoxifen-induced OHC-specific Neuroplastin knockout (*Nptn*^{fl/fl}; *Prestin-CreER*^{T2}) model and show that
665 continued expression of NEUROPLASTIN in OHCs of adult mice is required for the localisation of

666 PMCAs and the maintenance of normal hearing function (Fig 10). Moreover, reduced expression of
667 NEUROPLASTIN was directly correlated with PMCA2 expression at the membrane, which in turn was
668 correlated with hearing function. However, while membrane localisation of PMCAs was drastically
669 reduced in the absence of NEUROPLASTIN, some PMCA2 could still be detected correctly located at
670 the plasma membrane. This suggests that another protein, which is also able to act as a PMCA subunit,
671 may be partially substituting for the absence NEUROPLASTIN. Interestingly, it is the transmembrane
672 domain of NEUROPLASTIN that is critical for binding to PMCAs [44], and this domain is highly
673 conserved across members of the Basigin group of cell adhesion molecules [45]. As such, this particular
674 role of NEUROPLASTIN could potentially be undertaken by either BASIGIN or EMBIGIN. Notably,
675 *Embigin* was also identified as a hearing loss candidate gene by the IMPC programme [11].

676

677 **Neuroplastin genetically interacts with Cadherin 23**

678 Our finding that heterozygous *Nptn* mutant mice exhibit a high-frequency hearing loss has not
679 been reported for other *Nptn* models. Interestingly, this phenotype was completely absent after crossing
680 the *Nptn^{tm1b}* allele to a coisogenic background in which the C57BL/6 strain-specific hypomorphic
681 *Cdh23^{ahl}* allele has been corrected (*Cdh23^{753A>G}*) (Fig 11). The finding that heterozygous *Nptn^{tm1b/+}*
682 mutant mice on a 'corrected' C57BL/6N background display normal high-frequency hearing thresholds,
683 compared to *Nptn^{tm1b/+}* mutant mice on a standard C57BL/6N background, demonstrates a genetic
684 interaction between *Nptn* and *Cdh23*. Mechanistically, this is presumably acting through the previously
685 defined genetic interaction reported between *Atp2b2* (PMCA2) and *Cdh23*, where the hearing loss
686 phenotype exhibited by heterozygous PMCA2 mutant mice (*Atp2b2^{+/dfwi5}*) is elevated if one copy of the
687 *Cdh23^{ahl}* allele (+/*ahl*) is also present, and further elevated if homozygous (*ahl/ahl*) [30]. Together, these
688 data suggest that having only one wild type copy of *Nptn* (*Nptn^{+/tm1b}*) likely causes a reduction of PMCA2
689 localisation, leading to a hearing loss when compounded by the presence of the *Cdh23^{ahl}* allele, and
690 thereby phenocopying what has been reported for *Atp2b2* heterozygous lesions. Given this genetic
691 interaction, it is important to carefully consider the genetic background of *Nptn* mutant mice when

692 investigating the role of NEUROPLASTIN in the auditory system. Moreover, while to date no *NPTN*
693 mutations have been reported in patients with hearing loss, this has focused on searching for
694 homozygous or compound heterozygous *NPTN* lesions.

695 In humans, mutations in *CDH23* (ENSG00000107736) are associated with early-onset hearing
696 loss (USH1D and DFNB12) [46, 47], and have been implicated in cases of late-onset, progressive
697 hearing loss [48]. Given our data, and that a genetic interaction between *ATP2B2* and *CDH23* has been
698 demonstrated in humans [49], we suggest that patients carrying double *NPTN* and *CDH23* lesions
699 should be further investigated.

700 In conclusion, our data show that the primary cause of hearing loss in *Nptn*-null mice is due to
701 OHC dysfunction resulting from a reduction of correctly localised PMCA2, and this is exacerbated by
702 the secondary loss of afferent synapses.

703

704 **Methods**

705 **Ethical Approval**

706 All animal studies were licensed by the Home Office under the Animals (Scientific Procedures)
707 Act 1986, United Kingdom, and additionally approved by the relevant Institutional Ethical Review
708 Committees (PBF9BD884 to MRB and PCC8E5E93 to WM). Mice were housed under a 12 hour light/12
709 hour dark cycle and allowed access to food and water ad libitum. All conducted experiments complied
710 with The Journal's ethics policies.

711

712 **Mice**

713 *Nptn^{tm1b(EUCOMM)Hmgu}* (hereafter called *Nptn^{tm1b}*) were generated as part of the International Mouse
714 Phenotyping Consortium. These mice were produced through cre-mediated conversion of the 'knockout-
715 first' *tm1a* allele, which was achieved by treating IVF derived embryos with a cell-permeable Cre-

716 enzyme. In the converted tm1b allele, exons 5 and 6 of the Neuroplastin gene are deleted, leaving a
717 *lacZ* reporter cassette (Fig 1). Together exons 5 and 6 encode two critical regions, Ig3 and the
718 transmembrane domain, which are present in both *Nptn* splice isoforms; additionally, the *lacZ* cassette
719 contains a splice acceptor that subsumes normal splicing. Thus, no functional protein is expected to be
720 produced from the *Nptn^{tm1b}* allele. *Nptn^{tm1c(EUCOMM)Hmgu}* (hereafter called *Nptn^{fl}*) mice were generated by
721 crossing the tm1a allele to C57BL/6N mice producing Flp recombinase to remove the *lacZ* and *neo*
722 cassette. *Nptn^{fl}* mice functionally behave like wild type mice while retaining the LoxP sites flanking exons
723 5 and 6 (Fig 1B). The generation of conditional knockouts was achieved by crossing *Nptn^{fl}* mice to the
724 *Myo15-cre* [26] and *Prestin-creER^{T2}* [50] model lines, provided by C. Petit and T. Friedman (*Myo15-cre*)
725 and J. Zuo (*Prestin-creER^{T2}*).

726 *Myo15-cre* recombinant mice carry the cre recombinase gene driven by the Myosin-15 gene
727 promoter, which in the cochlea deletes floxed *Nptn* exons 5 and 6 specifically in hair cells from
728 approximately P4 [26]. *Nptn^{+fl}* female mice were crossed with *Nptn^{+fl};Myo15-cre⁺* males to generate six
729 genotypes (*Nptn^{+/+};Myo15-cre⁻*, *Nptn^{+fl};Myo15-cre⁻*, *Nptn^{fl/fl};Myo15-cre⁻*, *Nptn^{+/+};Myo15-cre⁺*,
730 *Nptn^{+fl};Myo15-cre⁺*, *Nptn^{fl/fl};Myo15-cre⁺*). For ABR analysis, all six genotypes were tested. To reduce
731 the number of mice generated, subsequent breedings were set up between *Nptn^{fl/fl}* and *Nptn^{fl/fl};Myo15-
732 cre⁺* mice to generate *Nptn^{fl/fl}* mice with, or without, the cre driver.

733 *Prestin-creERT2* recombinant mice carry the tamoxifen-inducible cre recombinase gene in the
734 *Prestin* locus following its stop codon, which deletes floxed *Nptn* exons 5 and 6 specifically in OHCs [50]
735 following delivery of tamoxifen. *Nptn^{fl/fl}* females were crossed with *Nptn^{fl/fl};Prestin-creER^{T2}+* males to
736 generate *Nptn^{fl/fl}* mice with or without the cre driver. Recombination was induced by tamoxifen delivered
737 by oral gavage (3 doses delivered over 3 days at 200 mg/kg) at 4 weeks of age, and ABRs and DPOAEs
738 were performed 7, and 14 days following the final tamoxifen dose, respectively.

739 The isoform-specific mutant, *Nptn^{Δexon2}* mutant line was generated by the Molecular and
740 Cellular Biology group at the MRC Harwell Institute. Using a CRISPR–Cas9-mediated deletion
741 approach, 941nt were deleted, spanning exon 2 (ENSMUSE00000961910, Fig 1C).

742 All mutant mouse models used were maintained on a C57BL/6NTac background, or on a
743 C57BL/6NTac;Cdh23-repaired background in which the hypomorphic *Cdh23^{ahl}* allele present in the
744 C57BL/6 background is corrected to wildtype (*Cdh23^{753A>G}*; Mianne, Chessum (27)). No sex-based
745 differences in phenotype were observed during the IMPC adult phenotyping pipeline; as such, both male
746 and female mice were used for all experiments.

747

748 **Auditory Brainstem Response (ABR)**

749 Analysis of hearing function by ABR was undertaken as previously described [41]. Briefly, mice
750 were anaesthetised with an I.P. injection of ketamine (100 mg ml⁻¹ at 10% v/v) and xylazine (20 mg ml⁻¹
751 at 5% v/v) administered at a rate of 0.1 ml/10 g body mass. Animals were placed on a heated mat inside
752 a sound-attenuated chamber (ETS-Lindgren), and electrodes were inserted sub-dermally; below the
753 right pinnae, into the muscle mass below the left ear, and at the cranial vertex. ABR responses were
754 collected, amplified, and averaged using the TDT RZ6 System 3 hardware in conjunction with BioSigRZ
755 (version 5.7.1) software (Tucker Davies Technology). Stimuli were delivered in the form of a 0.1 ms
756 broadband click, or as a single frequency tone at 6, 12, 18, 24, and 30 kHz (5 ms duration, 1 ms rise
757 and fall). All stimuli were presented in 5 dB falling steps from 90 dB SPL, and responses were averaged
758 over 512 (tone) or 300 (click) repeats. Following ABR recordings, mice were either culled by cervical
759 dislocation or recovered with a S.C. injection of atipamezole administered 1 mg kg⁻¹ body mass. For the
760 analysis of wave I, supra-threshold traces were further filtered between 400 - 2500Hz to remove
761 additional background noise. Amplitudes were calculated as the difference between the peak and valley.
762 Latencies were calculated as the time from onset to the wave peak.

763

764 **Distortion Product Otoacoustic Emissions (DPOAEs)**

765 To assess outer hair cell function in vivo, surgical anaesthesia was induced by intraperitoneal
766 injection of ketamine (100 mg ml⁻¹ at 10% v/v), xylazine (20 mg ml⁻¹ at 5% v/v) and acepromazine (2
767 mg ml⁻¹ at 8% v/v), administered at a rate of 0.1 ml/10 g body mass. Once the required depth of

768 anaesthesia was confirmed by the lack of the pedal reflex, a section of pinna was removed to allow
769 unobstructed access to the external auditory meatus. Mice were then placed on a heated mat inside a
770 sound-attenuated chamber (ETS-Lindgren) and the DPOAE probe assembly was inserted into the ear
771 canal using a pipette tip to aid correct placement. DPOAE tests were performed using frequency-specific
772 tone-burst stimuli at 6, 12, 18, 24, and 30 kHz with the TDT RZ6 System 3 hardware and BioSigRZ
773 (version 5.7.1) software (Tucker Davis Technology). An ER10B+ low noise probe microphone (Etymotic
774 Research) was used to measure the DPOAE near the tympanic membrane. Tone stimuli were presented
775 via separate MF1 (Tucker Davis Technology) speakers, with f_1 and f_2 at a ratio of $f_2/f_1 = 1.2$ ($L_1 = 65$ dB
776 SPL, $L_2 = 55$ dB SPL), centred around the frequencies of 6, 12, 18, 24, and 30 kHz. In-ear calibration
777 was performed before each test. The f_1 and f_2 tones were presented continuously and a fast-Fourier
778 transform was performed on the averaged response of 356 epochs (each approximately 21 ms). The
779 level of the $2f_1 - f_2$ DPOAE response was recorded and the noise floor was calculated by averaging
780 the four frequency bins on either side of the $2f_1 - f_2$ frequency. DPOAEs presented as the response
781 above the averaged noise floor. Following DPOAE recordings, mice were culled by cervical dislocation.

782

783 **Immunohistochemistry**

784 To assess protein localisation in the cochlea, animals were culled by cervical dislocation and
785 inner ears were removed and fixed by perfusion at the round and oval window with 4% PFA, followed
786 by 1 h submersion fixation on ice. For whole-mounts, ears were finely dissected to expose the sensory
787 epithelium. Sections were cut from whole tissues decalcified for 72 hr at 4°C in 3.5% EDTA,
788 cryoprotected with 30% sucrose, then embedded in OCT before cutting into 12 μ m slices on a cryostat.
789 For synaptic labelling, cochleae were permeabilised using PBS + 0.3% Triton X-100, blocked in 5%
790 donkey serum, and incubated at 37°C overnight (16-18 hr) with rabbit anti-Ribeye A domain (1:200,
791 Synaptic Systems Cat# 192 103, RRID:AB_2086775) and mouse anti-GluR2 (1:200, Millipore Cat#
792 MAB397, RRID:AB_2113875). For all other antibodies, cochleae were permeabilised with PBS + 0.1%
793 Triton X-100, blocked in 5% donkey serum + 1% BSA, and incubated with primary antibodies overnight

794 (16-18 hr) at 4°C. Primary antibodies: sheep anti-Np (1:200, R and D Systems Cat# AF7818,
795 RRID:AB_2715517), goat anti-Np65 (1:100, R and D Systems Cat# AF5360, RRID:AB_2155920),
796 mouse anti-PMCA 5F10 (1:200, Thermo Fisher Scientific Cat# MA3-914, RRID:AB_2061566), rabbit
797 anti-PMCA1 (1:200, Alomone Labs Cat# ACP-005, RRID:AB_2756567), rabbit anti-PMCA2 (1:200,
798 Abcam Cat# ab3529, RRID:AB_303878), rabbit anti-Neurofilament 200 (1:200, Sigma-Aldrich Cat#
799 N4142, RRID:AB_477272). To allow the detection of primary antibodies, cochleae were incubated with
800 a relevant fluorophore-conjugated secondary antibody for either 1 hr at room temperature or 2 hr at
801 37°C (synaptic labelling). Secondary antibodies: AlexaFluor-568 donkey anti-rabbit (1:500, Thermo
802 Fisher Scientific Cat# A10042, RRID:AB_2534017), Alexa Fluor-568 donkey anti-mouse (1:500,
803 Thermo Fisher Scientific Cat# A10037, RRID:AB_2534013), Alexa Fluor-488 donkey anti-rabbit (1:500,
804 Thermo Fisher Scientific Cat# A-21206, RRID:AB_2535792), Alexa Fluor-488 donkey anti-mouse
805 (1:500, Thermo Fisher Scientific Cat# A-21202, RRID:AB_141607), Alexa Fluor-488 donkey anti-sheep
806 (1:500, Thermo Fisher Scientific Cat# A-11015, RRID:AB_2534082), Alexa Fluor-568 donkey anti-goat
807 (1:500, Thermo Fisher Scientific Cat# A-11057, RRID:AB_2534104). Conjugated Phalloidin stains were
808 also used to visualise stereocilia bundles where required: Alexa Fluor-647 Phalloidin (1:200, Thermo
809 Fisher Scientific Cat# A22287), Alexa Fluor-488 Phalloidin (1:200, Thermo Fisher Scientific Cat#
810 A12379). Samples were visualised using a Zeiss LSM 710 with Airyscan detector under either 20x
811 magnification or 63x oil magnification (synapses). Images were processed using the Zeiss Zen
812 microscopy software and Fiji.

813

814 **Western Blot**

815 Membrane enriched lysates were extracted from whole cochlea using a Mem-PER plus
816 Membrane Protein Extraction kit (Thermo Scientific™; Cat# 89842). For each genotype, six pooled
817 cochleae (three mice) and a half brain were extracted into separate membrane and cytosolic enriched
818 lysates as per kit instructions. Glycosylation was removed from denatured extracted lysates using
819 PNGase F (NEB, Cat# P0704S) as per the manufacturer's protocol. Protein (10 mg) was separated with

820 SDS/PAGE and transferred onto 0.45 μm Nitrocellulose membranes (Invitrogen™, Cat# LC2001).
821 Membranes were blocked with 5% BSA for 1 hour at room temperature, then probed with sheep anti-
822 Np (1:1000, R and D Systems Cat# AF7818, RRID:AB_2715517), goat anti-Np65 (1:200, R and D
823 Systems Cat# AF5360, RRID:AB_2155920) overnight (16-18 hr) at 4°C. Equal loading was confirmed
824 with antibodies against β -actin (1:5000, Proteintech Cat# 60008-1-Ig, RRID:AB_2289225), α -tubulin
825 (1:1000, Thermo Fisher Scientific Cat# A11126, RRID:AB_2534135), or $\text{Na}^{2+}/\text{K}^{+}$ ATPase (1:5000,
826 Abcam Cat# ab76020, RRID:AB_1310695). For detection, membranes were incubated with either a
827 HRP-conjugated donkey anti-sheep antibody (1:5000, R and D Systems Cat# HAF016,
828 RRID:AB_562591), and imaged with a UVP ChemiDoc-It imaging system with a BioChemi HR camera;
829 or with a donkey anti-goat IRDye 800CW (1:10000, LI-COR Biosciences Cat# 925-32214,
830 RRID:AB_2687553), a donkey anti-mouse IRDye 800CW (1:10000, LI-COR Biosciences Cat# 926-
831 32212, RRID:AB_621847), or a donkey anti-rabbit IRDye 680RD (1:10000, LI-COR Biosciences Cat#
832 926-68073, RRID:AB_10954442) and imaged using the Odyssey CLx Infrared Imaging System (LI-
833 COR).

834

835 **Single-hair cell electrophysiology**

836 Inner and outer hair cells from *Nptn^{tm1b}* mice were studied in acutely dissected organs of Corti
837 from postnatal day 7 (P7) to P25, where the day of birth is P0. Animals were killed by cervical dislocation.
838 Cochleae were dissected in normal extracellular solution (in mM): 135 NaCl, 5.8 KCl, 1.3 CaCl_2 , 0.9
839 MgCl_2 , 0.7 NaH_2PO_4 , 5.6 D-glucose, 10 HEPES-NaOH. Sodium pyruvate (2 mM), MEM amino acids
840 solution (50X, without L-Glutamine) and MEM vitamins solution (100X) were added from concentrates
841 (Fisher Scientific, UK). The pH was adjusted to 7.5 (osmolality ~ 308 mmol kg^{-1}).

842 Voltage-clamp recordings were performed at room temperature (22-24°C) using an Optopatch
843 amplifier (Cairn Research Ltd, UK). For basolateral membrane current recordings, the patch pipette
844 contained the following intracellular solution (in mM): 131 KCl, 3 MgCl_2 , 1 EGTA-KOH, 5 Na_2ATP , 5
845 HEPES-KOH, 10 Na_2 -phosphocreatine (pH 7.3; osmolality ~ 296 mmol kg^{-1}). Mechanoelectrical

846 transduction recordings were performed using an intracellular solution containing (in mM): 131 CsCl, 3
847 MgCl₂, 1 EGTA-CsOH, 5 Na₂ATP, 0.3 Na₂GTP, 5 Hepes-CsOH, 10 Na₂-phosphocreatine (pH 7.3).
848 Patch pipettes were coated with surf wax. Data acquisition was controlled by pClamp software using a
849 Digidata 1440A board (Molecular Devices, USA). Recordings were low-pass filtered at 2.5 kHz (8-pole
850 Bessel) and sampled at 5 kHz. Data analysis was performed using Origin software (OriginLab, USA).
851 Membrane potentials were corrected for a liquid junction potential measured between electrode and
852 bath solutions, which was −4 mV.

853 Mechanoelectrical transducer (MET) currents were elicited by stimulating the hair bundles of
854 OHCs using a fluid-jet from a pipette (tip diameter 8-10 μm) driven by a piezoelectric disc as previously
855 described [2, 16, 51]. The pipette tip of the fluid-jet was positioned near to the bundles to elicit a maximal
856 MET current. Mechanical stimuli were applied as force-steps or saturating 50 Hz sinusoids (filtered at
857 0.25 kHz, 8-pole Bessel) with driving voltages of ± 40 V.

858

859 **Experimental Design and Statistical Analyses**

860 Mean values are quoted in text and figures as mean ± standard deviation (SD), except for ABR
861 data which is displayed as median ± interquartile range (IQR). Statistical comparisons of means were
862 made by analysis of variance (one-way or two-way ANOVA) followed by a suitable posttest, or by
863 Student's two-tailed t-test with or without correction for multiple comparisons. ABR thresholds were
864 second scored by an independent researcher blinded to genotype and overall trends and levels of
865 significance were confirmed to match. For the analysis of ABR thresholds where true values were out
866 of the range of our equipment, thresholds were given a value of 95 dB SPL and marked as “no response”
867 (NR).

868

869 **Acknowledgements**

870 The authors wish to thank: J Harrison, and MLC Ward staff for their assistance with mouse
871 husbandry and tamoxifen dosing; and, the Molecular and Cellular Biology group at the Harwell Institute
872 for generating the *Nptn*^{Δexon2} mice. This work was supported by: the BBSRC (BB/S006257/1 to W.M.
873 and M.R.B.); the Medical Research Council (MC_UP_1503/2 to M.R.B); and, the Royal National Institute
874 for Deaf People (G81 to S.D.M.B., W.M. and M.R.B.).

875


876 References

- 877 1. Ricci AJ, Wu YC, Fettiplace R. The endogenous calcium buffer and the time course of
878 transducer adaptation in auditory hair cells. *J Neurosci*. 1998;18(20):8261-77. Epub 1998/10/08.
879 PubMed PMID: 9763471; PubMed Central PMCID: PMCPMC6792854.
- 880 2. Corns LF, Johnson SL, Kros CJ, Marcotti W. Calcium entry into stereocilia drives adaptation of
881 the mechanoelectrical transducer current of mammalian cochlear hair cells. *Proc Natl Acad Sci U S A*.
882 2014;111(41):14918-23. Epub 2014/09/18. doi: 10.1073/pnas.1409920111. PubMed PMID: 25228765;
883 PubMed Central PMCID: PMCPMC4205606.
- 884 3. Johnson SL, Kuhn S, Franz C, Ingham N, Furness DN, Knipper M, et al. Presynaptic
885 maturation in auditory hair cells requires a critical period of sensory-independent spiking activity. *Proc*
886 *Natl Acad Sci U S A*. 2013;110(21):8720-5. Epub 2013/05/08. doi: 10.1073/pnas.1219578110.
887 PubMed PMID: 23650376; PubMed Central PMCID: PMCPMC3666720.
- 888 4. Ceriani F, Hendry A, Jeng JY, Johnson SL, Stephani F, Olt J, et al. Coordinated calcium
889 signalling in cochlear sensory and non-sensory cells refines afferent innervation of outer hair cells.
890 *EMBO J*. 2019;38(9). Epub 2019/02/26. doi: 10.15252/embj.201899839. PubMed PMID: 30804003;
891 PubMed Central PMCID: PMCPMC6484507.
- 892 5. Smalla KH, Matthies H, Langnase K, Shabir S, Bockers TM, Wyneken U, et al. The synaptic
893 glycoprotein neuroplastin is involved in long-term potentiation at hippocampal CA1 synapses. *Proc*
894 *Natl Acad Sci U S A*. 2000;97(8):4327-32. Epub 2000/04/12. doi: 10.1073/pnas.080389297. PubMed
895 PMID: 10759566; PubMed Central PMCID: PMCPMC18241.
- 896 6. Marzban H, Khanzada U, Shabir S, Hawkes R, Langnaese K, Smalla KH, et al. Expression of
897 the immunoglobulin superfamily neuroplastin adhesion molecules in adult and developing mouse
898 cerebellum and their localisation to parasagittal stripes. *J Comp Neurol*. 2003;462(3):286-301. Epub
899 2003/06/10. doi: 10.1002/cne.10719. PubMed PMID: 12794733.
- 900 7. Owczarek S, Berezin V. Neuroplastin: cell adhesion molecule and signaling receptor. *Int J*
901 *Biochem Cell Biol*. 2012;44(1):1-5. Epub 2011/11/01. doi: 10.1016/j.biocel.2011.10.006. PubMed
902 PMID: 22036663.
- 903 8. Beesley PW, Herrera-Molina R, Smalla KH, Seidenbecher C. The Neuroplastin adhesion
904 molecules: key regulators of neuronal plasticity and synaptic function. *J Neurochem*. 2014;131(3):268-
905 83. Epub 2014/07/22. doi: 10.1111/jnc.12816. PubMed PMID: 25040546.
- 906 9. Herrera-Molina R, Sarto-Jackson I, Montenegro-Venegas C, Heine M, Smalla KH,
907 Seidenbecher CI, et al. Structure of excitatory synapses and GABAA receptor localization at inhibitory
908 synapses are regulated by neuroplastin-65. *J Biol Chem*. 2014;289(13):8973-88. Epub 2014/02/21.
909 doi: 10.1074/jbc.M113.514992. PubMed PMID: 24554721; PubMed Central PMCID:
910 PMCPMC3979398.
- 911 10. Hori K, Katayama N, Kachi S, Kondo M, Kadomatsu K, Usukura J, et al. Retinal dysfunction in
912 basigin deficiency. *Invest Ophthalmol Vis Sci*. 2000;41(10):3128-33. Epub 2000/09/01. PubMed PMID:
913 10967074.





- 914 11. Bowl MR, Simon MM, Ingham NJ, Greenaway S, Santos L, Cater H, et al. A large scale
915 hearing loss screen reveals an extensive unexplored genetic landscape for auditory dysfunction. *Nat*
916 *Commun.* 2017;8(1):886. Epub 2017/10/14. doi: 10.1038/s41467-017-00595-4. PubMed PMID:
917 29026089; PubMed Central PMCID: PMC5638796.
- 918 12. Carrott L, Bowl MR, Aguilar C, Johnson SL, Chessum L, West M, et al. Absence of
919 Neuroplastin-65 Affects Synaptogenesis in Mouse Inner Hair Cells and Causes Profound Hearing
920 Loss. *J Neurosci.* 2016;36(1):222-34. Epub 2016/01/08. doi: 10.1523/JNEUROSCI.1808-15.2016.
921 PubMed PMID: 26740663; PubMed Central PMCID: PMC4701962.
- 922 13. Zeng WZ, Grillet N, Dewey JB, Trouillet A, Krey JF, Barr-Gillespie PG, et al. Neuroplastin
923 Isoform Np55 Is Expressed in the Stereocilia of Outer Hair Cells and Required for Normal Outer Hair
924 Cell Function. *J Neurosci.* 2016;36(35):9201-16. Epub 2016/09/02. doi: 10.1523/JNEUROSCI.0093-
925 16.2016. PubMed PMID: 27581460; PubMed Central PMCID: PMC5005726.
- 926 14. Lagnaese K, Beesley PW, Gundelfinger ED. Synaptic membrane glycoproteins gp65 and
927 gp55 are new members of the immunoglobulin superfamily. *J Biol Chem.* 1997;272(2):821-7. Epub
928 1997/01/10. doi: 10.1074/jbc.272.2.821. PubMed PMID: 8995369.
- 929 15. Lin X, Brunk MGK, Yuanxiang P, Curran AW, Zhang E, Stober F, et al. Neuroplastin
930 expression is essential for hearing and hair cell PMCA expression. *Brain Struct Funct.*
931 2021;226(5):1533-51. Epub 2021/04/13. doi: 10.1007/s00429-021-02269-w. PubMed PMID:
932 33844052; PubMed Central PMCID: PMC8096745.
- 933 16. Carlton AJ, Halford J, Underhill A, Jeng JY, Avenarius MR, Gilbert ML, et al. Loss of Baiap2l2
934 destabilizes the transducing stereocilia of cochlear hair cells and leads to deafness. *J Physiol.*
935 2021;599(4):1173-98. Epub 2020/11/06. doi: 10.1113/JP280670. PubMed PMID: 33151556; PubMed
936 Central PMCID: PMC7898316.
- 937 17. Jeng JY, Carlton AJ, Johnson SL, Brown SDM, Holley MC, Bowl MR, et al. Biophysical and
938 morphological changes in inner hair cells and their efferent innervation in the ageing mouse cochlea. *J*
939 *Physiol.* 2021;599(1):269-87. Epub 2020/11/13. doi: 10.1113/JP280256. PubMed PMID: 33179774.
- 940 18. Crawford AC, Evans MG, Fettiplace R. Activation and adaptation of transducer currents in
941 turtle hair cells. *J Physiol.* 1989;419:405-34. Epub 1989/12/01. doi: 10.1113/jphysiol.1989.sp017878.
942 PubMed PMID: 2621635; PubMed Central PMCID: PMC1190013.
- 943 19. Marcotti W, Kros CJ. Developmental expression of the potassium current $I_{K,n}$ contributes to
944 maturation of mouse outer hair cells. *J Physiol.* 1999;520 Pt 3:653-60. Epub 1999/11/02. doi:
945 10.1111/j.1469-7793.1999.00653.x. PubMed PMID: 10545133; PubMed Central PMCID:
946 PMC2269630.
- 947 20. Jeng JY, Johnson SL, Carlton AJ, De Tomasi L, Goodyear RJ, De Faveri F, et al. Age-related
948 changes in the biophysical and morphological characteristics of mouse cochlear outer hair cells. *J*
949 *Physiol.* 2020;598(18):3891-910. Epub 2020/07/02. doi: 10.1113/JP279795. PubMed PMID:
950 32608086.
- 951 21. Kros CJ, Ruppertsberg JP, Rusch A. Expression of a potassium current in inner hair cells
952 during development of hearing in mice. *Nature.* 1998;394(6690):281-4. Epub 1998/07/31. doi:
953 10.1038/28401. PubMed PMID: 9685158.
- 954 22. Marcotti W, Johnson SL, Kros CJ. Effects of intracellular stores and extracellular Ca^{2+} on
955 Ca^{2+} -activated K^{+} currents in mature mouse inner hair cells. *J Physiol.* 2004;557(Pt 2):613-33.
956 Epub 2004/04/06. doi: 10.1113/jphysiol.2003.060137. PubMed PMID: 15064328; PubMed Central
957 PMCID: PMC1665097.
- 958 23. Marcotti W, Johnson SL, Holley MC, Kros CJ. Developmental changes in the expression of
959 potassium currents of embryonic, neonatal and mature mouse inner hair cells. *J Physiol.* 2003;548(Pt
960 2):383-400. Epub 2003/02/18. doi: 10.1113/jphysiol.2002.034801. PubMed PMID: 12588897; PubMed
961 Central PMCID: PMC2342842.
- 962 24. Oliver D, Knipper M, Derst C, Fakler B. Resting potential and submembrane calcium
963 concentration of inner hair cells in the isolated mouse cochlea are set by KCNQ-type potassium
964 channels. *J Neurosci.* 2003;23(6):2141-9. Epub 2003/03/27. PubMed PMID: 12657673; PubMed
965 Central PMCID: PMC6742048.

- 966 25. Marcotti W, Geleoc GS, Lennan GW, Kros CJ. Transient expression of an inwardly rectifying
967 potassium conductance in developing inner and outer hair cells along the mouse cochlea. *Pflugers*
968 *Arch.* 1999;439(1-2):113-22. Epub 2000/01/29. doi: 10.1007/s004249900157. PubMed PMID:
969 10651007.
- 970 26. Caberlotto E, Michel V, Foucher I, Bahloul A, Goodyear RJ, Pepermans E, et al. Usher type
971 1G protein sans is a critical component of the tip-link complex, a structure controlling actin
972 polymerization in stereocilia. *Proc Natl Acad Sci U S A.* 2011;108(14):5825-30. Epub 2011/03/26. doi:
973 10.1073/pnas.1017114108. PubMed PMID: 21436032; PubMed Central PMCID: PMC3078398.
- 974 27. Mianne J, Chessum L, Kumar S, Aguilar C, Codner G, Hutchison M, et al. Correction of the
975 auditory phenotype in C57BL/6N mice via CRISPR/Cas9-mediated homology directed repair. *Genome*
976 *Med.* 2016;8(1):16. Epub 2016/02/16. doi: 10.1186/s13073-016-0273-4. PubMed PMID: 26876963;
977 PubMed Central PMCID: PMC4753642.
- 978 28. Schmidt N, Kollewe A, Constantin CE, Henrich S, Ritzau-Jost A, Bildl W, et al. Neuroplastin
979 and Basigin Are Essential Auxiliary Subunits of Plasma Membrane Ca(2+)-ATPases and Key
980 Regulators of Ca(2+) Clearance. *Neuron.* 2017;96(4):827-38 e9. Epub 2017/10/24. doi:
981 10.1016/j.neuron.2017.09.038. PubMed PMID: 29056295.
- 982 29. Dumont RA, Lins U, Filoteo AG, Penniston JT, Kachar B, Gillespie PG. Plasma membrane
983 Ca²⁺-ATPase isoform 2a is the PMCA of hair bundles. *J Neurosci.* 2001;21(14):5066-78. Epub
984 2001/07/05. PubMed PMID: 11438582; PubMed Central PMCID: PMC6762840.
- 985 30. Watson CJ, Tempel BL. A new *Atp2b2* deafwaddler allele, *dfw(i5)*, interacts strongly with
986 *Cdh23* and other auditory modifiers. *Hear Res.* 2013;304:41-8. Epub 2013/06/26. doi:
987 10.1016/j.heares.2013.06.003. PubMed PMID: 23792079; PubMed Central PMCID:
988 PMC3769430.
- 989 31. Stebbins WC, Hawkins JE, Jr., Johnson LG, Moody DB. Hearing thresholds with outer and
990 inner hair cell loss. *Am J Otolaryngol.* 1979;1(1):15-27. Epub 1979/01/01. doi: 10.1016/s0196-
991 0709(79)80004-6. PubMed PMID: 95382.
- 992 32. Assad JA, Hacohen N, Corey DP. Voltage dependence of adaptation and active bundle
993 movement in bullfrog saccular hair cells. *Proc Natl Acad Sci U S A.* 1989;86(8):2918-22. Epub
994 1989/04/01. doi: 10.1073/pnas.86.8.2918. PubMed PMID: 2468161; PubMed Central PMCID:
995 PMC287031.
- 996 33. Crawford AC, Evans MG, Fettiplace R. The actions of calcium on the mechano-electrical
997 transducer current of turtle hair cells. *J Physiol.* 1991;434:369-98. Epub 1991/03/01. doi:
998 10.1113/jphysiol.1991.sp018475. PubMed PMID: 1708822; PubMed Central PMCID:
999 PMC1181423.
- 1000 34. Ricci AJ, Fettiplace R. Calcium permeation of the turtle hair cell mechanotransducer channel
1001 and its relation to the composition of endolymph. *J Physiol.* 1998;506 (Pt 1):159-73. Epub 1998/03/03.
1002 doi: 10.1111/j.1469-7793.1998.159bx.x. PubMed PMID: 9481679; PubMed Central PMCID:
1003 PMC2230715.
- 1004 35. Herrera-Molina R, Mlinac-Jerkovic K, Ilic K, Stober F, Vemula SK, Sandoval M, et al.
1005 Neuroplastin deletion in glutamatergic neurons impairs selective brain functions and calcium
1006 regulation: implication for cognitive deterioration. *Sci Rep.* 2017;7(1):7273. Epub 2017/08/06. doi:
1007 10.1038/s41598-017-07839-9. PubMed PMID: 28779130; PubMed Central PMCID:
1008 PMC5544750.
- 1009 36. Korthals M, Langnaese K, Smalla KH, Kahne T, Herrera-Molina R, Handschuh J, et al. A
1010 complex of Neuroplastin and Plasma Membrane Ca(2+) ATPase controls T cell activation. *Sci Rep.*
1011 2017;7(1):8358. Epub 2017/08/23. doi: 10.1038/s41598-017-08519-4. PubMed PMID: 28827723;
1012 PubMed Central PMCID: PMC5566957.
- 1013 37. Ficarella R, Di Leva F, Bortolozzi M, Ortolano S, Donaudy F, Petrillo M, et al. A functional
1014 study of plasma-membrane calcium-pump isoform 2 mutants causing digenic deafness. *Proc Natl*
1015 *Acad Sci U S A.* 2007;104(5):1516-21. Epub 2007/01/20. doi: 10.1073/pnas.0609775104. PubMed
1016 PMID: 17234811; PubMed Central PMCID: PMC1785272.
- 1017 38. Zampini V, Ruttiger L, Johnson SL, Franz C, Furness DN, Waldhaus J, et al. *Eps8* regulates
1018 hair bundle length and functional maturation of mammalian auditory hair cells. *PLoS Biol.*


- 1019 2011;9(4):e1001048. Epub 2011/04/29. doi: 10.1371/journal.pbio.1001048. PubMed PMID: 21526224;
1020 PubMed Central PMCID: PMCPMC3079587.
- 1021 39. Marcotti W, van Netten SM, Kros CJ. The aminoglycoside antibiotic dihydrostreptomycin
1022 rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. *J Physiol.*
1023 2005;567(Pt 2):505-21. Epub 2005/07/05. doi: 10.1113/jphysiol.2005.085951. PubMed PMID:
1024 15994187; PubMed Central PMCID: PMCPMC1474200.
- 1025 40. Corns LF, Johnson SL, Roberts T, Ranatunga KM, Hendry A, Ceriani F, et al.
1026 Mechanotransduction is required for establishing and maintaining mature inner hair cells and
1027 regulating efferent innervation. *Nat Commun.* 2018;9(1):4015. Epub 2018/10/03. doi: 10.1038/s41467-
1028 018-06307-w. PubMed PMID: 30275467; PubMed Central PMCID: PMCPMC6167318.
- 1029 41. Dunbar LA, Patni P, Aguilar C, Mburu P, Corns L, Wells HR, et al. Clarin-2 is essential for
1030 hearing by maintaining stereocilia integrity and function. *EMBO Mol Med.* 2019;11(9):e10288. Epub
1031 2019/08/27. doi: 10.15252/emmm.201910288. PubMed PMID: 31448880; PubMed Central PMCID:
1032 PMCPMC6728604.
- 1033 42. Johnson SL, Kennedy HJ, Holley MC, Fettiplace R, Marcotti W. The resting transducer current
1034 drives spontaneous activity in prehearing mammalian cochlear inner hair cells. *J Neurosci.*
1035 2012;32(31):10479-83. Epub 2012/08/03. doi: 10.1523/JNEUROSCI.0803-12.2012. PubMed PMID:
1036 22855797; PubMed Central PMCID: PMCPMC3428842.
- 1037 43. Kim KX, Fettiplace R. Developmental changes in the cochlear hair cell mechanotransducer
1038 channel and their regulation by transmembrane channel-like proteins. *J Gen Physiol.*
1039 2013;141(1):141-8. Epub 2013/01/02. doi: 10.1085/jgp.201210913. PubMed PMID: 23277480;
1040 PubMed Central PMCID: PMCPMC3536526.
- 1041 44. Gong D, Chi X, Ren K, Huang G, Zhou G, Yan N, et al. Structure of the human plasma
1042 membrane Ca(2+)-ATPase 1 in complex with its obligatory subunit neuroplastin. *Nat Commun.*
1043 2018;9(1):3623. Epub 2018/09/08. doi: 10.1038/s41467-018-06075-7. PubMed PMID: 30190470;
1044 PubMed Central PMCID: PMCPMC6127144.
- 1045 45. Muramatsu T. Basigin (CD147), a multifunctional transmembrane glycoprotein with various
1046 binding partners. *J Biochem.* 2016;159(5):481-90. Epub 2015/12/20. doi: 10.1093/jb/mvv127. PubMed
1047 PMID: 26684586; PubMed Central PMCID: PMCPMC4846773.
- 1048 46. Bork JM, Peters LM, Riazuddin S, Bernstein SL, Ahmed ZM, Ness SL, et al. Usher syndrome
1049 1D and nonsyndromic autosomal recessive deafness DFNB12 are caused by allelic mutations of the
1050 novel cadherin-like gene CDH23. *Am J Hum Genet.* 2001;68(1):26-37. Epub 2000/11/25. doi:
1051 10.1086/316954. PubMed PMID: 11090341; PubMed Central PMCID: PMCPMC1234923.
- 1052 47. Bolz H, von Brederlow B, Ramirez A, Bryda EC, Kutsche K, Nothwang HG, et al. Mutation of
1053 CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D. *Nat*
1054 *Genet.* 2001;27(1):108-12. Epub 2001/01/04. doi: 10.1038/83667. PubMed PMID: 11138009.
- 1055 48. Kim BJ, Kim AR, Lee C, Kim SY, Kim NK, Chang MY, et al. Discovery of CDH23 as a
1056 Significant Contributor to Progressive Postlingual Sensorineural Hearing Loss in Koreans. *PLoS One.*
1057 2016;11(10):e0165680. Epub 2016/10/30. doi: 10.1371/journal.pone.0165680. PubMed PMID:
1058 27792758; PubMed Central PMCID: PMCPMC5085094.
- 1059 49. Schultz JM, Yang Y, Caride AJ, Filoteo AG, Penheiter AR, Lagziel A, et al. Modification of
1060 human hearing loss by plasma-membrane calcium pump PMCA2. *N Engl J Med.* 2005;352(15):1557-
1061 64. Epub 2005/04/15. doi: 10.1056/NEJMoa043899. PubMed PMID: 15829536.
- 1062 50. Fang J, Zhang WC, Yamashita T, Gao J, Zhu MS, Zuo J. Outer hair cell-specific prestin-
1063 CreERT2 knockin mouse lines. *Genesis.* 2012;50(2):124-31. Epub 2011/09/29. doi:
1064 10.1002/dvg.20810. PubMed PMID: 21954035; PubMed Central PMCID: PMCPMC3261330.
- 1065 51. Jeng JY, Harasztosi C, Carlton AJ, Corns LF, Marchetta P, Johnson SL, et al. MET currents
1066 and otoacoustic emissions from mice with a detached tectorial membrane indicate the extracellular
1067 matrix regulates Ca(2+) near stereocilia. *J Physiol.* 2021;599(7):2015-36. Epub 2021/02/10. doi:
1068 10.1113/JP280905. PubMed PMID: 33559882.
- 1069




Figure




Figure




Figure




Figure




Figure






Figure




Figure




Figure







Figure



D *Nptn*^{fl/fl}; *Prestin-CreER*^{T2+}; Tamoxifen+



Figure



Figure